<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Galderma Group AG (OTCPK:GALDY) Q3 2025 Sales Call October 23, 2025 9:30 AM EDT<br><br>Company Participants<br><br>Emil Ivanov - Head of Strategy, Investor Relations & ESG<br>Flemming Ornskov - CEO & Director<br>Thomas J.</td><td># ê°ˆë”ë§ˆ ê·¸ë£¹ AG (OTCPK:GALDY) 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ë°œí‘œ<br><br>2025ë…„ 10ì›” 23ì¼ ì˜¤ì „ 9ì‹œ 30ë¶„ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>ì—ë°€ ì´ë°”ë…¸í”„ (Emil Ivanov) - ì „ëµ, íˆ¬ìì ê´€ê³„ ë° ESG ë‹´ë‹¹ ì±…ì„ì<br>í”Œë ˆë° ì˜¨ìŠ¤ì½”ë¸Œ (Flemming Ornskov) - CEO ê²¸ ì´ì‚¬<br>í† ë§ˆìŠ¤ J.<br><br>---<br><br>**ë©´ì±…ì¡°í•­**: ì´ ë²ˆì—­ë³¸ì€ íˆ¬ììì˜ í¸ì˜ë¥¼ ìœ„í•´ ì œê³µë˜ëŠ” ê²ƒìœ¼ë¡œ, ì›ë¬¸ê³¼ ë²ˆì—­ë³¸ ê°„ ì°¨ì´ê°€ ìˆì„ ê²½ìš° ì˜ë¬¸ ì›ë³¸ì´ ìš°ì„ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Dittrich - Chief Financial Officer<br><br>Conference Call Participants<br><br>Thibault Boutherin - Morgan Stanley, Research Division<br>Harry Sefton<br>Shyam Kotadia - Goldman Sachs Group, Inc., Research Division<br>Benjamin Jackson - Jefferies LLC, Research Division<br>Yihan Li - Barclays Bank PLC, Research Division<br>Victor Floch - BNP Paribas Exane, Research Division<br>Richard Vosser - JPMorgan Chase & Co, Research Division<br>Natalia Webster - RBC Capital Markets, Research Division<br><br>Presentation<br><br>Operator<br><br>Good day, and thank you for standing by. Welcome to Galderma's conference call. [Operator Instructions] Please be advised that this conference is being recorded.</td><td>ë””íŠ¸ë¦¬íˆ - ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>í‹°ë³´ ë¶€í…Œë­ - ëª¨ê±´ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í•´ë¦¬ ì„¸í”„í„´<br>ìƒ´ ì½”íƒ€ë””ì•„ - ê³¨ë“œë§Œì‚­ìŠ¤ ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë²¤ìë¯¼ ì­ìŠ¨ - ì œí”„ë¦¬ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì´í•œ ë¦¬ - ë°”í´ë ˆì´ìŠ¤ ì€í–‰ PLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¹…í† ë¥´ í”Œë¡œí¬ - BNP íŒŒë¦¬ë°” ì—‘ì„¸ì¸, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¦¬ì²˜ë“œ ë³´ì„œ - JPëª¨ê±´ ì²´ì´ìŠ¤ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë‚˜íƒˆë¦¬ì•„ ì›¹ìŠ¤í„° - RBC ìºí”¼í„¸ ë§ˆì¼“, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ê¸°ë‹¤ë ¤ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê°ˆë”ë§ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ë³¸ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>I would now like to hand the conference over to Emil Ivanov, Head of Strategy, Investor Relations and ESG to introduce the call. Emil, please go ahead. Emil Ivanov<br>Head of Strategy, Investor Relations & ESG<br><br>Thank you very much. Welcome to Galderma's 2025 Third Quarter Trading Update Call. As customary, the press release was published at 7 a.m. Central European standard time today and can be viewed on our corporate website at any time. Today's presentation slides as well as a recording of the webcast will be made available on our website after the call.</td><td>ì§€ê¸ˆë¶€í„° ì»¨í¼ëŸ°ìŠ¤ë¥¼ ì „ëµ, íˆ¬ìì ê´€ê³„ ë° ESG ë‹´ë‹¹ ì±…ì„ìì¸ ì—ë°€ ì´ë°”ë…¸í”„(Emil Ivanov)ì—ê²Œ ë„˜ê²¨ í†µí™”ë¥¼ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì—ë°€, ì§„í–‰í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ì—ë°€ ì´ë°”ë…¸í”„<br>ì „ëµ, íˆ¬ìì ê´€ê³„ ë° ESG ë‹´ë‹¹ ì±…ì„ì<br><br>ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ê°ˆë”ë§ˆ(Galderma)ì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ì—…ë°ì´íŠ¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ê´€ë¡€ëŒ€ë¡œ ë³´ë„ìë£ŒëŠ” ì˜¤ëŠ˜ ì¤‘ì•™ìœ ëŸ½ í‘œì¤€ì‹œ ê¸°ì¤€ ì˜¤ì „ 7ì‹œì— ë°œí‘œë˜ì—ˆìœ¼ë©°, ì–¸ì œë“ ì§€ ë‹¹ì‚¬ ê¸°ì—… ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œ ìŠ¬ë¼ì´ë“œì™€ ì›¹ìºìŠ¤íŠ¸ ë…¹í™”ë³¸ì€ í†µí™” ì¢…ë£Œ í›„ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì— ê²Œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Please be advised that today's presentation contains forward-looking statements, which will be treated with the appropriate level of caution as advised on the slide. Let me now introduce today's trading update webcast, Dr. Flemming Ornskov, CEO of Galderma will provide performance highlights for the third quarter, Thomas Dittrich, CFO, will then present the trading update and the financial outlook for the full financial year. Both Flemming and Thomas will be available to answer questions from financial analysts before Flemming provide his final remarks to close the webcast. With this, I would like to invite Flemming to start Galderma's highlights for the third quarter of 2025.</td><td>ì˜¤ëŠ˜ ë°œí‘œì—ëŠ” ì „ë°©ìœ„ì  ì§„ìˆ (forward-looking statements)ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ìŠ¬ë¼ì´ë“œì— ì•ˆë‚´ëœ ë°”ì™€ ê°™ì´ ì ì ˆí•œ ìˆ˜ì¤€ì˜ ì£¼ì˜ë¥¼ ê¸°ìš¸ì—¬ ë‹¤ë£¨ì–´ì§ˆ ê²ƒì„ì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì˜¤ëŠ˜ì˜ ì‹¤ì  ì—…ë°ì´íŠ¸ ì›¹ìºìŠ¤íŠ¸ë¥¼ ì†Œê°œí•˜ê² ìŠµë‹ˆë‹¤. Galdermaì˜ CEOì¸ Flemming Ornskov ë°•ì‚¬ê»˜ì„œ 3ë¶„ê¸° ì‹¤ì  í•˜ì´ë¼ì´íŠ¸ë¥¼ ì œê³µí•˜ì‹¤ ê²ƒì´ë©°, ì´ì–´ì„œ CFOì¸ Thomas Dittrichê°€ ì‹¤ì  ì—…ë°ì´íŠ¸ì™€ ì „ì²´ íšŒê³„ì—°ë„ ì¬ë¬´ ì „ë§ì„ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. Flemmingê³¼ Thomas ë‘ ë¶„ ëª¨ë‘ ê¸ˆìœµ ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì˜ ì§ˆë¬¸ì— ë‹µë³€í•˜ì‹¤ ê²ƒì´ë©°, ì´í›„ Flemmingì´ ì›¹ìºìŠ¤íŠ¸ë¥¼ ë§ˆë¬´ë¦¬í•˜ëŠ” ìµœì¢… ë°œì–¸ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¼ Flemmingì„ ëª¨ì‹œê³  Galdermaì˜ 2025ë…„ 3ë¶„ê¸° í•˜ì´ë¼ì´íŠ¸ë¥¼ ì‹œì‘í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Flemming, over to you? Flemming Ornskov<br>CEO & Director<br><br>Thank you, Emil. Good morning, good afternoon, and welcome to Galderma's third quarter 2025 Trading Update webcast. In a year of opportunities, we delivered record net sales for the first 9 months along with strong commercial and innovation momentum across our portfolio. For the first nine months, Galderma delivered USD 3.7 billion in net sales. These results are ahead of expectation, driven by focused execution of both the existing portfolio and new innovation. Growth was driven primarily by volume, complemented by favorable mix. For the period, net sales growth was up 15% year-on-year at constant currency.</td><td>í”Œë ˆë°, ë§ì”€í•´ ì£¼ì‹œì£ ? í”Œë ˆë° ì˜¤ë¥¸ìŠ¤ì½”ë¸Œ<br>CEO ê²¸ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì—ë°€. ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤, ì¢‹ì€ ì˜¤í›„ì…ë‹ˆë‹¤. ê°ˆë”ë§ˆì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ì—…ë°ì´íŠ¸ ì›¹ìºìŠ¤íŠ¸ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ê¸°íšŒì˜ í•´ì—, ìš°ë¦¬ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì¹œ ê°•ë ¥í•œ ìƒì—…ì  ë° í˜ì‹  ëª¨ë©˜í…€ê³¼ í•¨ê»˜ 9ê°œì›”ê°„ ê¸°ë¡ì ì¸ ë§¤ì¶œì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 9ê°œì›” ë™ì•ˆ ê°ˆë”ë§ˆëŠ” 37ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ê¸°ì¡´ í¬íŠ¸í´ë¦¬ì˜¤ì™€ ì‹ ê·œ í˜ì‹  ëª¨ë‘ì— ëŒ€í•œ ì§‘ì¤‘ì ì¸ ì‹¤í–‰ì— í˜ì…ì–´ ì˜ˆìƒì„ ìƒíšŒí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì„±ì¥ì€ ì£¼ë¡œ íŒë§¤ëŸ‰ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìœ¼ë©°, ìœ ë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ê°€ ì´ë¥¼ ë³´ì™„í–ˆìŠµë‹ˆë‹¤. í•´ë‹¹ ê¸°ê°„ ë™ì•ˆ ë§¤ì¶œ ì„±ì¥ë¥ ì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ 15% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Growth for the third quarter was up 21% year-on-year at constant currency. This represents an acceleration across all geographies and product categories despite challenging market dynamics. The growth was especially strong for Nemluvio in the U.S. while neuromodulators benefit from some favorable phasing in the third quarter. Based on our strong growth trajectory across the portfolio and Nemluvio's performance, we are raising our full year guidance. For net sales growth, we expect to close the year between 17% and 17.7%. For core EBITDA, we expect a margin between 23.1% and 23.6%, both at constant currency.</td><td>3ë¶„ê¸° ì„±ì¥ë¥ ì€ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ëŒ€ë¹„ 21% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì–´ë ¤ìš´ ì‹œì¥ í™˜ê²½ì—ë„ ë¶ˆêµ¬í•˜ê³  ëª¨ë“  ì§€ì—­ê³¼ ì œí’ˆ ì¹´í…Œê³ ë¦¬ì—ì„œ ê°€ì†í™”ëœ ì„±ì¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. íŠ¹íˆ ë¯¸êµ­ ë‚´ Nemluvioì˜ ì„±ì¥ì´ ë‘ë“œëŸ¬ì¡Œìœ¼ë©°, ì‹ ê²½ì¡°ì ˆì œëŠ” 3ë¶„ê¸° ì¼ë¶€ ìœ ë¦¬í•œ ì‹œê¸°ì  ìš”ì¸ì˜ í˜œíƒì„ ë°›ì•˜ìŠµë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ ê°•ë ¥í•œ ì„±ì¥ ê¶¤ì ê³¼ Nemluvioì˜ ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. ìˆœë§¤ì¶œ ì„±ì¥ë¥ ì€ 17%ì—ì„œ 17.7% ì‚¬ì´ë¡œ ì—°ë§ì„ ë§ˆê°í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í•µì‹¬ EBITDA ë§ˆì§„ì€ 23.1%ì—ì„œ 23.6% ì‚¬ì´ë¥¼ ì˜ˆìƒí•˜ë©°, ëª¨ë‘ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our performance demonstrates our ability to deliver growth through commercial excellence, innovation and global expansion. Let's look at some highlights by product category on the next slide. Galderma continues on its strong growth momentum with net sales growth acceleration in the third quarter across all product categories and geographies. Galderma achieved double-digit growth in both injectable aesthetics and therapeutic dermatology reflecting broad-based growth momentum and successful commercial execution for the first 9 months of the year. Dermatological skincare continued on a strong trajectory, especially in international markets.</td><td>ìš°ë¦¬ì˜ ì‹¤ì ì€ ìƒì—…ì  ìš°ìˆ˜ì„±, í˜ì‹  ë° ê¸€ë¡œë²Œ í™•ì¥ì„ í†µí•´ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ì—­ëŸ‰ì„ ì…ì¦í•©ë‹ˆë‹¤. ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì—ì„œ ì œí’ˆ ì¹´í…Œê³ ë¦¬ë³„ ì£¼ìš” ë‚´ìš©ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ê°ˆë”ë§ˆëŠ” 3ë¶„ê¸°ì— ëª¨ë“  ì œí’ˆ ì¹´í…Œê³ ë¦¬ì™€ ì§€ì—­ì—ì„œ ë§¤ì¶œ ì„±ì¥ ê°€ì†í™”ë¥¼ ë³´ì´ë©° ê°•ë ¥í•œ ì„±ì¥ ëª¨ë©˜í…€ì„ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ê°ˆë”ë§ˆëŠ” ì—°ì´ˆ 9ê°œì›”ê°„ ê´‘ë²”ìœ„í•œ ì„±ì¥ ëª¨ë©˜í…€ê³¼ ì„±ê³µì ì¸ ìƒì—…ì  ì‹¤í–‰ì„ ë°˜ì˜í•˜ì—¬ ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆê³¼ ì¹˜ë£Œ í”¼ë¶€ê³¼ ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì€ íŠ¹íˆ í•´ì™¸ ì‹œì¥ì—ì„œ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ì§€ì†í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Globally, all 3 product categories outperform their respective markets. Both geographies delivered double-digit growth as did most of Galderma's top 10 markets. Our performance reflects focused commercial execution across our core business as well as incremental growth opportunities, as you'll see on the next slide. Let's start with injectable aesthetics, focusing on our neuromodulator portfolio. Our next-generation neuromodulator, Relfydess, continues to ramp up well in the 17 markets where it was already launched. Feedback remains very positive, and we are progressively gaining market share mainly from competitors.</td><td>ì „ ì„¸ê³„ì ìœ¼ë¡œ 3ê°œ ì œí’ˆ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ ê°ê°ì˜ ì‹œì¥ì„ ìƒíšŒí•˜ëŠ” ì„±ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì–‘ ì§€ì—­ ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, Galdermaì˜ ìƒìœ„ 10ê°œ ì‹œì¥ ëŒ€ë¶€ë¶„ë„ ë§ˆì°¬ê°€ì§€ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ í•µì‹¬ ì‚¬ì—… ì „ë°˜ì— ê±¸ì¹œ ì§‘ì¤‘ì ì¸ ì˜ì—… ì‹¤í–‰ê³¼ ì ì§„ì ì¸ ì„±ì¥ ê¸°íšŒë¥¼ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, ë‹¤ìŒ ìŠ¬ë¼ì´ë“œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆ(injectable aesthetics)ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) í¬íŠ¸í´ë¦¬ì˜¤ì— ì§‘ì¤‘í•˜ê² ìŠµë‹ˆë‹¤. ì°¨ì„¸ëŒ€ ì‹ ê²½ì¡°ì ˆì œì¸ RelfydessëŠ” ì´ë¯¸ ì¶œì‹œëœ 17ê°œ ì‹œì¥ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ìˆœì¡°ë¡­ê²Œ í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤. í”¼ë“œë°±ì€ ì—¬ì „íˆ ë§¤ìš° ê¸ì •ì ì´ë©°, ì£¼ë¡œ ê²½ìŸì‚¬ë¡œë¶€í„° ì ì§„ì ìœ¼ë¡œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I'm happy to share that we received 3 new approvals for Relfydess in Hong Kong, New Zealand and the United Arab Emirates. This last one arrived just in time for us to showcase Relfydess at the Aesthetic and Anti-Aging Medicine World Conference in Dubai. The conference took place in early October, and you can see some visuals on the right side of the slide. There was a lot of excitement. We look forward to the launch next year in a market where we currently do not have a neuromodulator offering. We also completed multiple additional Relfydess submissions globally progressing in our plans to have the broadest neuromodulator portfolio globally.</td><td>ë í”¼ë°ìŠ¤(Relfydess)ê°€ í™ì½©, ë‰´ì§ˆëœë“œ, ì•„ëì—ë¯¸ë¦¬íŠ¸ì—ì„œ 3ê±´ì˜ ì‹ ê·œ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ ìŠ¹ì¸ì€ ë‘ë°”ì´ì—ì„œ ì—´ë¦° ë¯¸ìš© ë° í•­ë…¸í™” ì˜í•™ ì„¸ê³„ ì»¨í¼ëŸ°ìŠ¤(Aesthetic and Anti-Aging Medicine World Conference)ì—ì„œ ë í”¼ë°ìŠ¤ë¥¼ ì„ ë³´ì´ê¸°ì— ë”± ë§ëŠ” ì‹œê¸°ì— ë„ì°©í–ˆìŠµë‹ˆë‹¤. ì´ ì»¨í¼ëŸ°ìŠ¤ëŠ” 10ì›” ì´ˆì— ê°œìµœë˜ì—ˆìœ¼ë©°, ìŠ¬ë¼ì´ë“œ ì˜¤ë¥¸ìª½ì—ì„œ ê´€ë ¨ ì´ë¯¸ì§€ë¥¼ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜„ì¥ì—ì„œ ë§ì€ ê´€ì‹¬ì´ ìˆì—ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) ì œí’ˆì´ ì—†ëŠ” ì‹œì¥ì—ì„œ ë‚´ë…„ ì¶œì‹œë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì „ ì„¸ê³„ì ìœ¼ë¡œ ê°€ì¥ ê´‘ë²”ìœ„í•œ ì‹ ê²½ì¡°ì ˆì œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê² ë‹¤ëŠ” ê³„íšì— ë”°ë¼ ë í”¼ë°ìŠ¤ì— ëŒ€í•œ ì—¬ëŸ¬ ì¶”ê°€ ìŠ¹ì¸ ì‹ ì²­ì„ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The neuromodulator subcategories overall has been performing really well with market share gains in the U.S. and in international markets. If we focus on the European countries where Relfydess is launched, we see early signals demonstrating the strength of our neuromodulator portfolio strategy. Over the past 12 months, our neuromodulator portfolio gained 490 basis points of market share. And in the third quarter, the portfolio delivered double-digit growth with Dysport growing well and Relfydess continuing to ramp up. Moving now to fillers and biostimulators, where we continue to invest for growth.</td><td>ì‹ ê²½ì¡°ì ˆì œ í•˜ìœ„ ì¹´í…Œê³ ë¦¬ ì „ë°˜ì´ ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ì—ì„œ ì‹œì¥ì ìœ ìœ¨ ìƒìŠ¹ê³¼ í•¨ê»˜ ë§¤ìš° ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Relfydessê°€ ì¶œì‹œëœ ìœ ëŸ½ êµ­ê°€ë“¤ì— ì§‘ì¤‘í•´ë³´ë©´, ìš°ë¦¬ì˜ ì‹ ê²½ì¡°ì ˆì œ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµì˜ ê°•ì ì„ ë³´ì—¬ì£¼ëŠ” ì´ˆê¸° ì‹ í˜¸ë“¤ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ 12ê°œì›” ë™ì•ˆ ìš°ë¦¬ì˜ ì‹ ê²½ì¡°ì ˆì œ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 490bpì˜ ì‹œì¥ì ìœ ìœ¨ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  3ë¶„ê¸°ì—ëŠ” Dysportì˜ ê²¬ì¡°í•œ ì„±ì¥ê³¼ Relfydessì˜ ì§€ì†ì ì¸ í™•ëŒ€ì— í˜ì…ì–´ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì„±ì¥ì„ ìœ„í•œ íˆ¬ìë¥¼ ì§€ì†í•˜ê³  ìˆëŠ” í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We gained further market share in fillers and biostimulators in international markets and in the U.S. Restylane continued to be impacted by a soft filler market, while Sculptra maintained a very strong growth trajectory with double-digit growth across geographies. I would like to showcase 2 specific efforts, which are stimulating growth for this category. First, global activities on our proven injectable treatments for improving facial appearance, after medication driven weight loss. We believe that we are best positioned in this space with our clinically proven portfolio of Sculptra and the full Restylane range.</td><td>ìš°ë¦¬ëŠ” í•„ëŸ¬ì™€ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ë¶€ë¬¸ì—ì„œ í•´ì™¸ ì‹œì¥ê³¼ ë¯¸êµ­ ì‹œì¥ ëª¨ë‘ì—ì„œ ì¶”ê°€ì ì¸ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ë ˆìŠ¤í‹¸ë Œì€ ë¶€ì§„í•œ í•„ëŸ¬ ì‹œì¥ì˜ ì˜í–¥ì„ ê³„ì† ë°›ì•˜ì§€ë§Œ, ìŠ¤ì»¬íŠ¸ë¼ëŠ” ì „ ì§€ì—­ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ ê¶¤ë„ë¥¼ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ì´ ì¹´í…Œê³ ë¦¬ì˜ ì„±ì¥ì„ ì´‰ì§„í•˜ê³  ìˆëŠ” ë‘ ê°€ì§€ êµ¬ì²´ì ì¸ ë…¸ë ¥ì„ ì†Œê°œí•˜ê³ ì í•©ë‹ˆë‹¤. ì²«ì§¸, ì•½ë¬¼ ê¸°ë°˜ ì²´ì¤‘ ê°ëŸ‰ í›„ ì•ˆë©´ ì™¸ëª¨ ê°œì„ ì„ ìœ„í•œ ë‹¹ì‚¬ì˜ ê²€ì¦ëœ ì£¼ì‚¬ ì¹˜ë£Œì œì— ëŒ€í•œ ê¸€ë¡œë²Œ í™œë™ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„ìƒì ìœ¼ë¡œ ì…ì¦ëœ ìŠ¤ì»¬íŠ¸ë¼ì™€ ì „ì²´ ë ˆìŠ¤í‹¸ë Œ ë¼ì¸ì—… í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í†µí•´ ì´ ë¶„ì•¼ì—ì„œ ìµœê³ ì˜ ì…ì§€ë¥¼ ê°–ì¶”ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We provide leading education and training for health care professionals leveraging the first of its client clinical trial data focused on patients experiencing [ patient ] volume loss associated with the medication driven weight loss. We also commissioned clinical consensus guidelines which set a standard approach for identifying and managing the unique needs of this patient population. And in the U.S., we launched a significant direct-to-consumer campaign called Sculpt & Lift, targeting patients on GLP-1 treatment.</td><td>ì €í¬ëŠ” ì˜ë£Œ ì „ë¬¸ê°€ë“¤ì„ ìœ„í•œ ì„ ë„ì ì¸ êµìœ¡ ë° í›ˆë ¨ì„ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì•½ë¬¼ ê¸°ë°˜ ì²´ì¤‘ ê°ëŸ‰ê³¼ ê´€ë ¨ëœ [í™˜ì] ë³¼ë¥¨ ì†ì‹¤ì„ ê²½í—˜í•˜ëŠ” í™˜ìë“¤ì— ì´ˆì ì„ ë§ì¶˜ ìµœì´ˆì˜ ì„ìƒì‹œí—˜ ë°ì´í„°ë¥¼ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ëŸ¬í•œ í™˜ìêµ°ì˜ ê³ ìœ í•œ ìš”êµ¬ì‚¬í•­ì„ ì‹ë³„í•˜ê³  ê´€ë¦¬í•˜ê¸° ìœ„í•œ í‘œì¤€ ì ‘ê·¼ë²•ì„ ì œì‹œí•˜ëŠ” ì„ìƒ í•©ì˜ ê°€ì´ë“œë¼ì¸ì„ ì˜ë¢°í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ì—ì„œëŠ” GLP-1 ì¹˜ë£Œë¥¼ ë°›ëŠ” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ 'Sculpt & Lift'ë¼ëŠ” ëŒ€ê·œëª¨ ì†Œë¹„ì ì§ì ‘ ëŒ€ìƒ ìº í˜ì¸ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We believe this is an important opportunity to increase demand for the category and for the Galderma offering as the campaign aims to bring medication driven weight loss patients to aesthetic practices. This includes patients who may not have been aesthetic users before. Second, we continue to scale recently launched differentiated innovation. This includes the ramp-up of Restylane shape in Brazil, which created a total new segment as a bone-mimicking fillers, it offers an outcome, which could previously only be achieved with invasive plastic surgery. The launch continues to progress strongly with a positive halo effect on the rest of the portfolio of Restylane in the market.</td><td>ì €í¬ëŠ” ì´ê²ƒì´ ì¹´í…Œê³ ë¦¬ì™€ ê°ˆë”ë§ˆ ì œí’ˆì— ëŒ€í•œ ìˆ˜ìš”ë¥¼ ì¦ê°€ì‹œí‚¬ ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ê¸°íšŒë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. ì´ ìº í˜ì¸ì€ ì•½ë¬¼ ê¸°ë°˜ ì²´ì¤‘ ê°ëŸ‰ í™˜ìë“¤ì„ ë¯¸ìš© ì‹œìˆ  í´ë¦¬ë‹‰ìœ¼ë¡œ ìœ ë„í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì´ì „ì— ë¯¸ìš© ì‹œìˆ ì„ ì´ìš©í•˜ì§€ ì•Šì•˜ë˜ í™˜ìë“¤ë„ í¬í•¨ë©ë‹ˆë‹¤. <br><br>ë‘˜ì§¸, ì €í¬ëŠ” ìµœê·¼ ì¶œì‹œëœ ì°¨ë³„í™”ëœ í˜ì‹  ì œí’ˆë“¤ì˜ ê·œëª¨ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¸Œë¼ì§ˆì—ì„œì˜ ë ˆìŠ¤í‹¸ë Œ ì‰ì´í”„(Restylane Shape) í™•ëŒ€ê°€ í¬í•¨ë˜ëŠ”ë°, ì´ ì œí’ˆì€ ë¼ˆë¥¼ ëª¨ë°©í•˜ëŠ” í•„ëŸ¬ë¡œì„œ ì™„ì „íˆ ìƒˆë¡œìš´ ì„¸ê·¸ë¨¼íŠ¸ë¥¼ ì°½ì¶œí–ˆìœ¼ë©°, ì´ì „ì—ëŠ” ì¹¨ìŠµì ì¸ ì„±í˜•ìˆ˜ìˆ ë¡œë§Œ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆë˜ ê²°ê³¼ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ì´ ì œí’ˆì˜ ì¶œì‹œëŠ” ì‹œì¥ ë‚´ ë ˆìŠ¤í‹¸ë Œ í¬íŠ¸í´ë¦¬ì˜¤ ì „ì²´ì— ê¸ì •ì ì¸ í›„ê´‘ íš¨ê³¼ë¥¼ ë¯¸ì¹˜ë©° ê°•ë ¥í•˜ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The other significant launch was Sculptra in China which is on a very strong growth trajectory. Our Chinese team has been executing an exemplary omni launch strategy to increase awareness and penetration. Two of the achievements I find particularly impressive. Over 100,000 units were sold in the first 6 months of the launch. Sculptra is already the #1 searched brand in biostimulator [indiscernible] with over 200 million impressions. Switching now to Dermatological skincare, we continue to focus on the core of our business, while also introducing new innovation to capture opportunities for further growth. Starting with Cetaphil. We further expanded its range to address white spaces.</td><td>ë˜ ë‹¤ë¥¸ ì£¼ìš” ì¶œì‹œëŠ” ì¤‘êµ­ì—ì„œì˜ ìŠ¤ì»¬íŠ¸ë¼(Sculptra)ì˜€ìœ¼ë©°, ì´ëŠ” ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ ê¶¤ë„ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ íŒ€ì€ ì¸ì§€ë„ì™€ ì¹¨íˆ¬ìœ¨ì„ ë†’ì´ê¸° ìœ„í•´ ëª¨ë²”ì ì¸ ì˜´ë‹ˆì±„ë„ ì¶œì‹œ ì „ëµì„ ì‹¤í–‰í•´ ì™”ìŠµë‹ˆë‹¤. íŠ¹íˆ ì¸ìƒì ì´ë¼ê³  ìƒê°í•˜ëŠ” ë‘ ê°€ì§€ ì„±ê³¼ê°€ ìˆìŠµë‹ˆë‹¤. ì¶œì‹œ í›„ ì²« 6ê°œì›” ë™ì•ˆ 10ë§Œ ìœ ë‹› ì´ìƒì´ íŒë§¤ë˜ì—ˆìŠµë‹ˆë‹¤. ìŠ¤ì»¬íŠ¸ë¼ëŠ” ì´ë¯¸ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° [ë¶ˆëª…í™•] ë¶„ì•¼ì—ì„œ ê°€ì¥ ë§ì´ ê²€ìƒ‰ë˜ëŠ” ë¸Œëœë“œ 1ìœ„ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©°, 2ì–µ íšŒ ì´ìƒì˜ ë…¸ì¶œì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ë¡œ ì „í™˜í•˜ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¹„ì¦ˆë‹ˆìŠ¤ì˜ í•µì‹¬ì— ê³„ì† ì§‘ì¤‘í•˜ëŠ” ë™ì‹œì—, ì¶”ê°€ ì„±ì¥ ê¸°íšŒë¥¼ í¬ì°©í•˜ê¸° ìœ„í•œ ìƒˆë¡œìš´ í˜ì‹ ë„ ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì„¸íƒ€í•„(Cetaphil)ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í™”ì´íŠ¸ ìŠ¤í˜ì´ìŠ¤(ë¯¸ê°œì²™ ì‹œì¥)ë¥¼ ê³µëµí•˜ê¸° ìœ„í•´ ì œí’ˆ ë¼ì¸ì„ ë”ìš± í™•ëŒ€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This included 2 totally transformative launches in the U.S., creating entirely new categories based on proven science. First, the skin activate a hydrating and firming line. It marks an entirely new skincare category of advanced hydration and firming solutions this time specifically to improve the amperage of aging, thinning and fragile skin. This also marks our first step in strengthening our position in the faster-growing hands and body lotion segment, where we historically have been underrepresented in the U.S. Second, the nourishing oil to foam cleanser represents a breakthrough in high-grading cleansers for sensitive skin.</td><td>ì´ëŠ” ì…ì¦ëœ ê³¼í•™ì„ ê¸°ë°˜ìœ¼ë¡œ ì™„ì „íˆ ìƒˆë¡œìš´ ì¹´í…Œê³ ë¦¬ë¥¼ ì°½ì¶œí•˜ëŠ” ë¯¸êµ­ ë‚´ 2ê°œì˜ í˜ì‹ ì ì¸ ì œí’ˆ ì¶œì‹œë¥¼ í¬í•¨í–ˆìŠµë‹ˆë‹¤. ì²«ì§¸, ìŠ¤í‚¨ ì•¡í‹°ë² ì´íŠ¸(Skin Activate) í•˜ì´ë“œë ˆì´íŒ… ì•¤ í¼ë° ë¼ì¸ì…ë‹ˆë‹¤. ì´ëŠ” ë…¸í™”, ì–‡ì•„ì§ ë° ì·¨ì•½í•œ í”¼ë¶€ì˜ ì™¸ê´€ì„ ê°œì„ í•˜ê¸° ìœ„í•´ íŠ¹ë³„íˆ ê³ ì•ˆëœ ì§„ë³´ëœ ìˆ˜ë¶„ ê³µê¸‰ ë° íƒ„ë ¥ ì†”ë£¨ì…˜ì´ë¼ëŠ” ì™„ì „íˆ ìƒˆë¡œìš´ ìŠ¤í‚¨ì¼€ì–´ ì¹´í…Œê³ ë¦¬ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ëŠ” ë˜í•œ ìš°ë¦¬ê°€ ì—­ì‚¬ì ìœ¼ë¡œ ë¯¸êµ­ì—ì„œ ì €ì¡°í•œ ì ìœ ìœ¨ì„ ë³´ì˜€ë˜ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” í•¸ë“œ ì•¤ ë°”ë”” ë¡œì…˜ ë¶€ë¬¸ì—ì„œ ìš°ë¦¬ì˜ ì…ì§€ë¥¼ ê°•í™”í•˜ëŠ” ì²« ë²ˆì§¸ ë‹¨ê³„ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ë‘˜ì§¸, ë„ˆë¦¬ì‹± ì˜¤ì¼ íˆ¬ í¼ í´ë Œì €(Nourishing Oil to Foam Cleanser)ëŠ” ë¯¼ê°ì„± í”¼ë¶€ë¥¼ ìœ„í•œ ê³ ê¸‰ í´ë Œì € ë¶€ë¬¸ì—ì„œì˜ íšê¸°ì ì¸ ì œí’ˆì„ ì˜ë¯¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>This first of its kind formula is designed to deeply cleanse while preserving hydration and supporting the sensitive skin's moisture barrier. As the essential first step in any skincare regime, it also removes sunscreen and makeup, making it ideal for double-cleansing or a stand-alone use. In addition, Galderma continued to roll out recent innovation in international markets. This includes multiple Cetaphil lines, especially in the fast-growing Asian and Latin American markets. We're also using these to strengthen our position globally and capture local opportunities. For example, the gentle exfoliating SA line was launched in China, strengthening our offering in the face segment.</td><td>ì´ ìµœì´ˆì˜ í¬ë®¬ëŸ¬ëŠ” ìˆ˜ë¶„ì„ ë³´ì¡´í•˜ë©´ì„œ ê¹Šì€ í´ë Œì§•ì„ ì œê³µí•˜ê³  ë¯¼ê°ì„± í”¼ë¶€ì˜ ìˆ˜ë¶„ ì¥ë²½ì„ ì§€ì›í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ëª¨ë“  ìŠ¤í‚¨ì¼€ì–´ ë£¨í‹´ì˜ í•„ìˆ˜ì ì¸ ì²« ë‹¨ê³„ë¡œì„œ, ìì™¸ì„  ì°¨ë‹¨ì œì™€ ë©”ì´í¬ì—…ë„ ì œê±°í•˜ì—¬ ì´ì¤‘ ì„¸ì•ˆì´ë‚˜ ë‹¨ë… ì‚¬ìš©ì— ì´ìƒì ì…ë‹ˆë‹¤. ë˜í•œ ê°ˆë”ë§ˆëŠ” ìµœê·¼ í˜ì‹  ì œí’ˆë“¤ì„ êµ­ì œ ì‹œì¥ì— ì§€ì†ì ìœ¼ë¡œ ì¶œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” íŠ¹íˆ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì•„ì‹œì•„ ë° ë¼í‹´ ì•„ë©”ë¦¬ì¹´ ì‹œì¥ì—ì„œ ì—¬ëŸ¬ ì„¸íƒ€í•„ ë¼ì¸ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì œí’ˆë“¤ì„ í™œìš©í•˜ì—¬ ê¸€ë¡œë²Œ ì…ì§€ë¥¼ ê°•í™”í•˜ê³  í˜„ì§€ ê¸°íšŒë¥¼ í¬ì°©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ì  í‹€ ì—‘ìŠ¤í´ë¦¬ì—ì´íŒ… SA ë¼ì¸ì´ ì¤‘êµ­ì—ì„œ ì¶œì‹œë˜ì–´ í˜ì´ì…œ ì„¸ê·¸ë¨¼íŠ¸ì—ì„œ ìš°ë¦¬ì˜ ì œí’ˆêµ°ì„ ê°•í™”í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For Alastin, the preferred periprocedural skincare brand in the U.S., we broadened our reach and leverage synergies with our injectable aesthetics portfolio. Following an exclusive launch for our partnering health care professionals, we initiated a broad consumer outreach for our restorative skin complex with next-generation TriHex Technology. This has been another successful launch turning the improved formula into one of Alastin's top-selling products. It also received Elle Magazine's Future of Beauty Award for top skin tightening cream, reinforcing its position for medication driven weight-loss patients. Second, we continue to expand Alastin in international markets.</td><td>ë¯¸êµ­ ë‚´ ì„ í˜¸ë˜ëŠ” ì‹œìˆ  ì „í›„ ìŠ¤í‚¨ì¼€ì–´ ë¸Œëœë“œì¸ Alastinì˜ ê²½ìš°, ìš°ë¦¬ëŠ” ë„ë‹¬ ë²”ìœ„ë¥¼ í™•ëŒ€í•˜ê³  ì£¼ì‚¬í˜• ë¯¸ìš© í¬íŠ¸í´ë¦¬ì˜¤ì™€ì˜ ì‹œë„ˆì§€ë¥¼ í™œìš©í–ˆìŠµë‹ˆë‹¤. íŒŒíŠ¸ë„ˆ ì˜ë£Œ ì „ë¬¸ê°€ë“¤ì„ ìœ„í•œ ë…ì  ì¶œì‹œì— ì´ì–´, ì°¨ì„¸ëŒ€ TriHex ê¸°ìˆ ì´ ì ìš©ëœ restorative skin complexì— ëŒ€í•œ ê´‘ë²”ìœ„í•œ ì†Œë¹„ì í™ë³´ë¥¼ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê°œì„ ëœ í¬ë®¬ëŸ¬ë¥¼ Alastinì˜ ìµœê³  íŒë§¤ ì œí’ˆ ì¤‘ í•˜ë‚˜ë¡œ ë§Œë“¤ë©° ë˜ ë‹¤ë¥¸ ì„±ê³µì ì¸ ì¶œì‹œê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ Elle Magazineì˜ Future of Beauty Awardì—ì„œ ìµœê³ ì˜ í”¼ë¶€ íƒ„ë ¥ í¬ë¦¼ìœ¼ë¡œ ì„ ì •ë˜ì–´, ì•½ë¬¼ ê¸°ë°˜ ì²´ì¤‘ ê°ëŸ‰ í™˜ìë“¤ì„ ìœ„í•œ ì œí’ˆìœ¼ë¡œì„œì˜ ì…ì§€ë¥¼ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ë‘˜ì§¸, ìš°ë¦¬ëŠ” Alastinì˜ í•´ì™¸ ì‹œì¥ í™•ì¥ì„ ì§€ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the launch of China, we're excited about to introduce Alastin to the second largest precision dispense market globally. Turning to therapeutic dermatology. Nemluvio remains on a strong trajectory, especially in the U.S. Nemluvio continues to surpass expectations underpinned by growing demand and increased access. This is reflected in Nemluvio's growing share of total prescriptions and paid new patient starts. If we look at the 6-week rolling average of paid new patient start, also known as NBRx from September to early October. Nemluvio was trending at about 37% market share in prurigo nodularis and 7.3% in atopic dermatitis.</td><td>ì¤‘êµ­ ì‹œì¥ ì¶œì‹œì™€ ê´€ë ¨í•˜ì—¬, ì €í¬ëŠ” ì „ ì„¸ê³„ì—ì„œ ë‘ ë²ˆì§¸ë¡œ í° ì „ë¬¸ì˜ì•½í’ˆ ì‹œì¥ì— ì•Œë¼ìŠ¤í‹´ì„ ì†Œê°œí•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¹˜ë£Œ í”¼ë¶€ê³¼ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤ëŠ” íŠ¹íˆ ë¯¸êµ­ì—ì„œ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤ëŠ” ì¦ê°€í•˜ëŠ” ìˆ˜ìš”ì™€ í™•ëŒ€ëœ ì ‘ê·¼ì„±ì— í˜ì…ì–´ ê¸°ëŒ€ì¹˜ë¥¼ ì§€ì†ì ìœ¼ë¡œ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë„´ë£¨ë¹„ì˜¤ì˜ ì „ì²´ ì²˜ë°© ì¤‘ ì ìœ ìœ¨ ì¦ê°€ì™€ ìœ ë£Œ ì‹ ê·œ í™˜ì ì‹œì‘ ê±´ìˆ˜ ì¦ê°€ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. 9ì›”ë¶€í„° 10ì›” ì´ˆê¹Œì§€ 6ì£¼ ì´ë™í‰ê·  ê¸°ì¤€ ìœ ë£Œ ì‹ ê·œ í™˜ì ì‹œì‘ ê±´ìˆ˜, ì¦‰ NBRxë¥¼ ì‚´í´ë³´ë©´, ë„´ë£¨ë¹„ì˜¤ëŠ” ê²°ì ˆì„± ì–‘ì§„ì—ì„œ ì•½ 37%ì˜ ì‹œì¥ ì ìœ ìœ¨ì„, ì•„í† í”¼ í”¼ë¶€ì—¼ì—ì„œëŠ” 7.3%ì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As a result, atopic dermatitis sales became the larger contributor in the third quarter. Overall, the majority of patients starting on Nemluvio were new -- yes, new to advanced therapy. This demonstrates the value perceived from Nemluvio in these indications by health care professionals who have prescribed the product to their patients. Last, but of course, not least, we continue to expand access for patients. The percentage of patients covered by commercial plans with broad access to reimbursement has surpassed 80%. For both indications, Nemluvio is reimbursed as a first-line biologic treatment with no need to first go through another therapy.</td><td>ê·¸ ê²°ê³¼, 3ë¶„ê¸°ì—ëŠ” ì•„í† í”¼ í”¼ë¶€ì—¼ ë§¤ì¶œì´ ë” í° ê¸°ì—¬ë¥¼ í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë„´ë£¨ë¹„ì˜¤ë¥¼ ì‹œì‘í•˜ëŠ” í™˜ìì˜ ëŒ€ë‹¤ìˆ˜ëŠ” ì‹ ê·œ í™˜ìì˜€ìŠµë‹ˆë‹¤ -- ë„¤, ê³ ê¸‰ ì¹˜ë£Œë²•ì„ ì²˜ìŒ ì ‘í•˜ëŠ” ì‹ ê·œ í™˜ìë“¤ì´ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì œí’ˆì„ í™˜ìë“¤ì—ê²Œ ì²˜ë°©í•œ ì˜ë£Œ ì „ë¬¸ê°€ë“¤ì´ ì´ëŸ¬í•œ ì ì‘ì¦ì—ì„œ ë„´ë£¨ë¹„ì˜¤ì˜ ê°€ì¹˜ë¥¼ ì¸ì •í•˜ê³  ìˆìŒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ë¬¼ë¡  ë§¤ìš° ì¤‘ìš”í•œ ì ì€, ìš°ë¦¬ê°€ í™˜ìë“¤ì˜ ì ‘ê·¼ì„±ì„ ê³„ì† í™•ëŒ€í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê´‘ë²”ìœ„í•œ ë³´í—˜ ê¸‰ì—¬ ì ‘ê·¼ì„±ì„ ì œê³µí•˜ëŠ” ìƒì—… ë³´í—˜ í”Œëœì˜ ì ìš©ì„ ë°›ëŠ” í™˜ì ë¹„ìœ¨ì´ 80%ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤. ë‘ ì ì‘ì¦ ëª¨ë‘ì—ì„œ ë„´ë£¨ë¹„ì˜¤ëŠ” 1ì°¨ ìƒë¬¼í•™ì  ì œì œ ì¹˜ë£Œì œë¡œ ê¸‰ì—¬ê°€ ì ìš©ë˜ë©°, ë‹¤ë¥¸ ì¹˜ë£Œë²•ì„ ë¨¼ì € ê±°ì¹  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Meanwhile, in international markets, Nemluvio's uptake continues to be strong in Germany. We have now launched Nemluvio in Austria, Switzerland, the United Kingdom and Denmark while progressing on price negotiations with multiple other markets where Nemluvio is already accrued. A number of additional regulatory submissions globally are also in profits. As you can see, Galderma continues to perform strongly advancing our growth drivers across the portfolio and reinforcing our leadership in dermatology through new data presentations and world-class education programs.</td><td>í•œí¸, í•´ì™¸ ì‹œì¥ì—ì„œëŠ” Nemluvioì˜ ë…ì¼ ë‚´ ì‹œì¥ ì¹¨íˆ¬ê°€ ì§€ì†ì ìœ¼ë¡œ ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì˜¤ìŠ¤íŠ¸ë¦¬ì•„, ìŠ¤ìœ„ìŠ¤, ì˜êµ­, ë´ë§ˆí¬ì—ì„œ Nemluvioë¥¼ ì¶œì‹œí–ˆìœ¼ë©°, Nemluvioê°€ ì´ë¯¸ ìŠ¹ì¸ëœ ì—¬ëŸ¬ ì‹œì¥ì—ì„œ ê°€ê²© í˜‘ìƒì„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ ë‹¤ìˆ˜ì˜ ì¶”ê°€ ê·œì œ ë‹¹êµ­ ì œì¶œ ê±´ë“¤ë„ ì§„í–‰ ì¤‘ì— ìˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼, GaldermaëŠ” í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ì„±ì¥ ë™ë ¥ì„ ë°œì „ì‹œí‚¤ê³ , ìƒˆë¡œìš´ ë°ì´í„° ë°œí‘œì™€ ì„¸ê³„ì  ìˆ˜ì¤€ì˜ êµìœ¡ í”„ë¡œê·¸ë¨ì„ í†µí•´ í”¼ë¶€ê³¼ ë¶„ì•¼ì—ì„œì˜ ë¦¬ë”ì‹­ì„ ê°•í™”í•˜ë©° ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì‹¤ì ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I'd now like to hand over to Thomas to cover the sales performance in more detail as well as the outlook for the remainder of the year. Thomas? Thomas J. Dittrich<br>Chief Financial Officer<br><br>Thank you, Flemming. It's my pleasure to comment on Galderma's Q3 2025 trading update and outlook, starting with an overview of net sales for the period. As mentioned by Flemming, Galderma continued on its strong momentum, achieving a record USD 3.737 billion in net sales for the first 9 months of the year, up 15% year-on-year at constant currency. For the third quarter, this represented an acceleration to 21% year-on-year growth at constant currency.</td><td>ì´ì œ í† ë§ˆìŠ¤ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê²¨ ë§¤ì¶œ ì‹¤ì ê³¼ ì—°ë§ê¹Œì§€ì˜ ì „ë§ì— ëŒ€í•´ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. í† ë§ˆìŠ¤?<br><br>Thomas J. Dittrich<br>ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í”Œë ˆë°. Galdermaì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ì—…ë°ì´íŠ¸ì™€ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ë¨¼ì € í•´ë‹¹ ê¸°ê°„ì˜ ìˆœë§¤ì¶œ ê°œìš”ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. í”Œë ˆë°ì´ ì–¸ê¸‰í–ˆë“¯ì´, GaldermaëŠ” ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ì´ì–´ê°€ë©° ì˜¬í•´ 9ê°œì›”ê°„ ê¸°ë¡ì ì¸ 37ì–µ 3,700ë§Œ ë‹¬ëŸ¬ì˜ ìˆœë§¤ì¶œì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ëŒ€ë¹„ 15% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. 3ë¶„ê¸°ì˜ ê²½ìš°, ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 21% ì„±ì¥ìœ¼ë¡œ ê°€ì†í™”ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This was higher than expected for the quarter based on strong performance across the portfolio and especially from Nemluvio's ramp up along with some favorable phasing in neuromodulators. Growth was broad-based and continues to be driven by volume, complemented by favorable mix which more than offset adverse price impact. Looking now at injectable aesthetics, net sales were USD 1.871 billion, up 10.5% year-on-year at constant currency. Neuromodulator net sales were USD 1.053 billion, up 14.0% year-on-year at constant currency. Both the U.S. and international markets delivered double-digit growth, outperforming the market and gaining share.</td><td>ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì€ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ ê°•ë ¥í•œ ì„±ê³¼, íŠ¹íˆ Nemluvioì˜ ë§¤ì¶œ ì¦ê°€ì„¸ì™€ ì‹ ê²½ì¡°ì ˆì œ ë¶€ë¬¸ì˜ ì¼ë¶€ ìœ ë¦¬í•œ ì‹œê¸°ì  ìš”ì¸ì— í˜ì…ì–´ ì˜ˆìƒë³´ë‹¤ ë†’ì•˜ìŠµë‹ˆë‹¤. ì„±ì¥ì€ ì „ë°˜ì ìœ¼ë¡œ ê³ ë¥´ê²Œ ë‚˜íƒ€ë‚¬ìœ¼ë©°, íŒë§¤ëŸ‰ ì¦ê°€ê°€ ì£¼ë„í•˜ê³  ìœ ë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ê°€ ì´ë¥¼ ë³´ì™„í•˜ì—¬ ê°€ê²© í•˜ë½ ì˜í–¥ì„ ìƒì‡„í•˜ê³ ë„ ë‚¨ì•˜ìŠµë‹ˆë‹¤. ì´ì œ ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆì„ ì‚´í´ë³´ë©´, ìˆœë§¤ì¶œì€ 18ì–µ 7,100ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ 10.5% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œ ìˆœë§¤ì¶œì€ 10ì–µ 5,300ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ 14.0% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í•˜ë©° ì‹œì¥ì„ ì•ì„œê³  ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Growth was driven by strong performance of Dysport in both the U.S. and international markets, along with the ongoing ramp-up of Relfydess. Neuromodulator growth in the third quarter was 12.6% in constant currency, ahead of expectations, benefiting from strong execution as well as some favorable phasing between the third and the fourth quarter. Fillers and biostimulators net sales were USD 818 million, up 6.2% at constant currency for the first 9 months. Again, Galderma grew faster than the market and gained share in both the U.S. and international markets.</td><td>ì´ëŸ¬í•œ ì„±ì¥ì€ ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ ëª¨ë‘ì—ì„œ ë””ìŠ¤í¬íŠ¸(Dysport)ì˜ ê°•ë ¥í•œ ì‹¤ì ê³¼ ë¦´íŒŒì´ë°ìŠ¤(Relfydess)ì˜ ì§€ì†ì ì¸ í™•ëŒ€ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. 3ë¶„ê¸° ì‹ ê²½ì¡°ì ˆì œ ë§¤ì¶œì€ ìƒìˆ˜í™˜ìœ¨ ê¸°ì¤€ 12.6% ì„±ì¥í•˜ì—¬ ì˜ˆìƒì„ ìƒíšŒí–ˆìœ¼ë©°, ì´ëŠ” ê°•ë ¥í•œ ì‹¤í–‰ë ¥ê³¼ í•¨ê»˜ 3ë¶„ê¸°ì™€ 4ë¶„ê¸° ê°„ ì¼ë¶€ ìœ ë¦¬í•œ ì‹œê¸°ì  ìš”ì¸ì˜ í˜œíƒì„ ë°›ì•˜ìŠµë‹ˆë‹¤. í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ìˆœë§¤ì¶œì€ 9ê°œì›” ëˆ„ì  ê¸°ì¤€ ìƒìˆ˜í™˜ìœ¨ ê¸°ì¤€ 6.2% ì¦ê°€í•œ 8ì–µ 1,800ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê°ˆë”ë§ˆëŠ” ë‹¤ì‹œ í•œë²ˆ ì‹œì¥ë³´ë‹¤ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ë©° ë¯¸êµ­ê³¼ í•´ì™¸ ì‹œì¥ ëª¨ë‘ì—ì„œ ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While fillers overall continue to be impacted by market softness, Galderma's performance was supported by the growth of differentiated products and especially new launches, including Restylane SHAYPE in Brazil, as Flemming presented earlier. Biostimulators maintained very strong momentum with outstanding double-digit growth in both geographies. Sculptra remains our fastest-growing injectable aesthetics brand. Growth was especially behind in the international markets with widespread performance and strong contribution from China, where we just launched the brand earlier this year. Next, moving to dermatological skincare.</td><td>í•„ëŸ¬ ì „ë°˜ì ìœ¼ë¡œëŠ” ì‹œì¥ ì¹¨ì²´ì˜ ì˜í–¥ì„ ê³„ì† ë°›ê³  ìˆì§€ë§Œ, ê°ˆë”ë§ˆì˜ ì‹¤ì ì€ ì°¨ë³„í™”ëœ ì œí’ˆë“¤ì˜ ì„±ì¥ê³¼ íŠ¹íˆ ì‹ ì œí’ˆ ì¶œì‹œì— í˜ì…ì–´ ë’·ë°›ì¹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ì•ì„œ í”Œë ˆë°ì´ ë°œí‘œí•œ ë°”ì™€ ê°™ì´ ë¸Œë¼ì§ˆì˜ ë ˆìŠ¤í‹¸ë Œ ì‰ì´í”„(Restylane SHAYPE)ë¥¼ í¬í•¨í•œ ì‹ ì œí’ˆë“¤ì´ ê·¸ ì˜ˆì…ë‹ˆë‹¤. ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„°ëŠ” ì–‘ ì§€ì—­ ëª¨ë‘ì—ì„œ ë‘ ìë¦¿ìˆ˜ì˜ ë›°ì–´ë‚œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ë©° ë§¤ìš° ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ìŠ¤ì»¬íŠ¸ë¼(Sculptra)ëŠ” ì—¬ì „íˆ ìš°ë¦¬ì˜ ì£¼ì‚¬ ë¯¸ìš© ë¸Œëœë“œ ì¤‘ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ êµ­ì œ ì‹œì¥ì—ì„œ ì„±ì¥ì´ ë‘ë“œëŸ¬ì¡Œìœ¼ë©°, ê´‘ë²”ìœ„í•œ ì‹¤ì ê³¼ í•¨ê»˜ ì˜¬í•´ ì´ˆ ë¸Œëœë“œë¥¼ ë§‰ ì¶œì‹œí•œ ì¤‘êµ­ì˜ ê°•ë ¥í•œ ê¸°ì—¬ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ì œ ë”ë§ˆí†¨ë¡œì§€ì»¬ ìŠ¤í‚¨ì¼€ì–´ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Net sales for the first 9 months were USD 1.063 billion with year-on-year growth of 8.2% at constant currency. Galderma outgrew the market in dermatological skincare globally with the majority of our key markets gaining share despite some constrained consumer spending. Growth in dermatological skincare was led by international markets, our larger geographies, where both Cetaphil and Alastin grew double digit. I would also be remiss not to mention Cetaphil's continued outstanding trajectory in fast-growing Asian markets, especially in India and China. In the U.S., performance was impacted by constrained consumer spending. Nonetheless, Cetaphil in the U.S.</td><td>ì²« 9ê°œì›”ê°„ ìˆœë§¤ì¶œì€ 10ì–µ 6,300ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 8.2% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. GaldermaëŠ” ì¼ë¶€ ì†Œë¹„ì ì§€ì¶œ ìœ„ì¶•ì—ë„ ë¶ˆêµ¬í•˜ê³  ëŒ€ë¶€ë¶„ì˜ ì£¼ìš” ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ë©° ì „ ì„¸ê³„ ë”ë§ˆí†¨ë¡œì§€ì»¬ ìŠ¤í‚¨ì¼€ì–´ ì‹œì¥ì—ì„œ ì‹œì¥ ì„±ì¥ë¥ ì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ë”ë§ˆí†¨ë¡œì§€ì»¬ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì˜ ì„±ì¥ì€ í•´ì™¸ ì‹œì¥, íŠ¹íˆ ìš°ë¦¬ì˜ ëŒ€í˜• ì§€ì—­ì—ì„œ ì£¼ë„ë˜ì—ˆìœ¼ë©°, Cetaphilê³¼ Alastin ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì•„ì‹œì•„ ì‹œì¥, íŠ¹íˆ ì¸ë„ì™€ ì¤‘êµ­ì—ì„œ Cetaphilì´ ì§€ì†ì ìœ¼ë¡œ ë›°ì–´ë‚œ ì„±ì¥ ê¶¤ì ì„ ë³´ì´ê³  ìˆë‹¤ëŠ” ì ì„ ì–¸ê¸‰í•˜ì§€ ì•Šì„ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ì†Œë¹„ì ì§€ì¶œ ìœ„ì¶•ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ë¯¸êµ­ ë‚´ Cetaphilì€...</td></tr>
<tr><td>saw positive responses late in the third quarter from multiple promotional activities. Meanwhile, Alastin continued to deliver double-digit growth in the U.S. Now on to therapeutic dermatology. Net sales reached USD 804 million for the first 9 months of 2025, up 40.4% year-on-year in constant currency. Growth was driven by Nemluvio's continued outperformance, which more than offset the expected decline in the mature portfolio. Nemluvio's net sales for the first 9 months were USD 263 million, predominantly from the U.S. and prurigo nodularis. However, atopic dermatitis representing the larger market opportunity overtook prurigo nodularis sales in the third quarter for the first time.</td><td>3ë¶„ê¸° í›„ë°˜ì— ì—¬ëŸ¬ í”„ë¡œëª¨ì…˜ í™œë™ì„ í†µí•´ ê¸ì •ì ì¸ ë°˜ì‘ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. í•œí¸, ì•Œë¼ìŠ¤í‹´ì€ ë¯¸êµ­ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì¹˜ë£Œ í”¼ë¶€ê³¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2025ë…„ 9ê°œì›”ê°„ ìˆœë§¤ì¶œì€ 8ì–µ 400ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ê³ ì •í™˜ìœ¨ ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 40.4% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì€ ë„¤ë¯ˆë£¨ë¹„ì˜¤ì˜ ì§€ì†ì ì¸ ì´ˆê³¼ ë‹¬ì„±ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ì„±ìˆ™ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì˜ˆìƒëœ ê°ì†Œë¶„ì„ ìƒì‡„í•˜ê³ ë„ ë‚¨ì•˜ìŠµë‹ˆë‹¤. ë„¤ë¯ˆë£¨ë¹„ì˜¤ì˜ 9ê°œì›”ê°„ ìˆœë§¤ì¶œì€ 2ì–µ 6,300ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì£¼ë¡œ ë¯¸êµ­ê³¼ ê²°ì ˆì„± ì–‘ì§„ì—ì„œ ë°œìƒí–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë” í° ì‹œì¥ ê¸°íšŒë¥¼ ë‚˜íƒ€ë‚´ëŠ” ì•„í† í”¼ í”¼ë¶€ì—¼ì´ 3ë¶„ê¸°ì— ì²˜ìŒìœ¼ë¡œ ê²°ì ˆì„± ì–‘ì§„ ë§¤ì¶œì„ ì¶”ì›”í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As formulary coverage for patient reimbursement increased significantly, the results for the third quarter reflect managed carry rebates resulting from securing commercial coverage. For the mature portfolio, excluding Nemluvio, performance was impacted by anticipated lower volumes and pricing pressures globally, especially in the U.S. Nonetheless, we also saw some positive momentum in international markets where we capitalized on our strong portfolio in acne and rosacea. Now looking at net sales geographically for the first 9 months of the year.</td><td>í™˜ì ìƒí™˜ì„ ìœ„í•œ ë³´í—˜ê¸‰ì—¬ ì ìš© ë²”ìœ„ê°€ í¬ê²Œ í™•ëŒ€ë¨ì— ë”°ë¼, 3ë¶„ê¸° ì‹¤ì ì€ ìƒì—…ì  ë³´í—˜ ì ìš©ì„ í™•ë³´í•˜ë©´ì„œ ë°œìƒí•œ ê´€ë¦¬í˜• ë¦¬ë² ì´íŠ¸ë¥¼ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. Nemluvioë¥¼ ì œì™¸í•œ ì„±ìˆ™ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê²½ìš°, ì „ ì„¸ê³„ì ìœ¼ë¡œ, íŠ¹íˆ ë¯¸êµ­ì—ì„œ ì˜ˆìƒëœ ë¬¼ëŸ‰ ê°ì†Œì™€ ê°€ê²© ì••ë°•ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³ , ì—¬ë“œë¦„ ë° ì£¼ì‚¬ ë¶„ì•¼ì—ì„œ ê°•ë ¥í•œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™œìš©í•œ í•´ì™¸ ì‹œì¥ì—ì„œëŠ” ê¸ì •ì ì¸ ëª¨ë©˜í…€ë„ í™•ì¸í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ì œ ì—°ì´ˆ 9ê°œì›”ê°„ì˜ ì§€ì—­ë³„ ìˆœë§¤ì¶œì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The majority of our top 10 markets grew double digits with particularly high performance in key international markets, such as India, China, Mexico, Germany and the U.K. and Ireland. Both reporting geographies accelerated their growth momentum, noting the U.S. growth was especially fueled by the Nemluvio ramp-up. International, which remains the larger of our 2 reporting geographies, continued its strong growth momentum with 13.2% net sales growth at constant currency. Injectable Aesthetics delivered double-digit growth in most key international markets, including in Europe, Latin America and Asia Pacific.</td><td>ìš°ë¦¬ì˜ ìƒìœ„ 10ëŒ€ ì‹œì¥ ëŒ€ë¶€ë¶„ì´ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, íŠ¹íˆ ì¸ë„, ì¤‘êµ­, ë©•ì‹œì½”, ë…ì¼, ì˜êµ­ ë° ì•„ì¼ëœë“œì™€ ê°™ì€ ì£¼ìš” í•´ì™¸ ì‹œì¥ì—ì„œ ë†’ì€ ì‹¤ì ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ë‘ ë³´ê³  ì§€ì—­ ëª¨ë‘ ì„±ì¥ ëª¨ë©˜í…€ì´ ê°€ì†í™”ë˜ì—ˆìœ¼ë©°, íŠ¹íˆ ë¯¸êµ­ ì„±ì¥ì€ Nemluvioì˜ ë§¤ì¶œ í™•ëŒ€ì— í˜ì…ì€ ë°”ê°€ ì»¸ìŠµë‹ˆë‹¤. ë‘ ë³´ê³  ì§€ì—­ ì¤‘ ë” í° ê·œëª¨ì¸ í•´ì™¸ ì§€ì—­ì€ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ 13.2%ì˜ ìˆœë§¤ì¶œ ì„±ì¥ìœ¼ë¡œ ê°•ë ¥í•œ ì„±ì¥ ëª¨ë©˜í…€ì„ ì´ì–´ê°”ìŠµë‹ˆë‹¤. ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆì€ ìœ ëŸ½, ë¼í‹´ì•„ë©”ë¦¬ì¹´, ì•„ì‹œì•„íƒœí‰ì–‘ì„ í¬í•¨í•œ ëŒ€ë¶€ë¶„ì˜ ì£¼ìš” í•´ì™¸ ì‹œì¥ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Both neuromodulators and fillers and biostimulators grew double digits, outpacing the market and gaining share. Neuromodulators saw growth across markets. Flemming already shared some highlights for Europe, which delivered the greatest growth contribution supported by the launch of Relfydess. Growth for neuromodulators in the third quarter also benefited as mentioned by some favorable phasing relative to the fourth quarter. For fillers and biostimulators, Restylane gained share in most key markets against a soft backdrop for fillers. As for Sculptra, we delivered strong growth and outstanding performance across international markets with some markets growing even triple digits.</td><td>ì‹ ê²½ì¡°ì ˆì œì™€ í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì‹œì¥ì„ ì•ì„œê³  ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œëŠ” ëª¨ë“  ì‹œì¥ì—ì„œ ì„±ì¥ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. í”Œë ˆë°ì´ ì´ë¯¸ ìœ ëŸ½ì˜ ì£¼ìš” ì„±ê³¼ë¥¼ ê³µìœ í–ˆëŠ”ë°, Relfydess ì¶œì‹œì— í˜ì…ì–´ ê°€ì¥ í° ì„±ì¥ ê¸°ì—¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 3ë¶„ê¸° ì‹ ê²½ì¡°ì ˆì œ ì„±ì¥ì€ ì•ì„œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ 4ë¶„ê¸° ëŒ€ë¹„ ìœ ë¦¬í•œ ì‹œê¸°ì  ìš”ì¸ì˜ í˜œíƒë„ ë°›ì•˜ìŠµë‹ˆë‹¤. í•„ëŸ¬ì™€ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„°ì˜ ê²½ìš°, Restylaneì€ í•„ëŸ¬ ì‹œì¥ì˜ ë¶€ì§„í•œ ë°°ê²½ ì†ì—ì„œë„ ëŒ€ë¶€ë¶„ì˜ ì£¼ìš” ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. Sculptraì˜ ê²½ìš°, êµ­ì œ ì‹œì¥ ì „ë°˜ì—ì„œ ê°•ë ¥í•œ ì„±ì¥ê³¼ íƒì›”í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©° ì¼ë¶€ ì‹œì¥ì—ì„œëŠ” ì„¸ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ê¸°ë„ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This includes markets where Sculptra is already well established especially in Latin America. Following the launch earlier this year, Sculptra continues its strong ramp up in China, the second largest injectable aesthetics market globally. Dermatological skincare also delivered double-digit growth internationally, ahead of the market, driven especially by continued outstanding growth of Cetaphil in Asia, especially in China and India. Alastin also contributed to strong growth from the ongoing international expansion, albeit from a smaller base. Therapeutic Dermatology growth was primarily driven by the ongoing rollout of Nemluvio also internationally. Moving now to the U.S.</td><td>ì´ëŠ” Sculptraê°€ ì´ë¯¸ í™•ê³ íˆ ìë¦¬ì¡ì€ ì‹œì¥ë“¤, íŠ¹íˆ ë¼í‹´ì•„ë©”ë¦¬ì¹´ë¥¼ í¬í•¨í•©ë‹ˆë‹¤. ì˜¬í•´ ì´ˆ ì¶œì‹œ ì´í›„, SculptraëŠ” ì „ ì„¸ê³„ì—ì„œ ë‘ ë²ˆì§¸ë¡œ í° ì£¼ì‚¬í˜• ë¯¸ìš© ì‹œì¥ì¸ ì¤‘êµ­ì—ì„œ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ë„ ì‹œì¥ì„ ì•ì„œëŠ” ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ êµ­ì œì ìœ¼ë¡œ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” íŠ¹íˆ ì•„ì‹œì•„, íŠ¹íˆ ì¤‘êµ­ê³¼ ì¸ë„ì—ì„œ Cetaphilì˜ ì§€ì†ì ì´ê³  íƒì›”í•œ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. Alastin ë˜í•œ ì‘ì€ ê¸°ë°˜ì—ì„œ ì¶œë°œí–ˆì§€ë§Œ ì§€ì†ì ì¸ êµ­ì œ í™•ì¥ì„ í†µí•´ ê°•ë ¥í•œ ì„±ì¥ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ì¹˜ë£Œ í”¼ë¶€ê³¼ ë¶€ë¬¸ì˜ ì„±ì¥ì€ ì£¼ë¡œ Nemluvioì˜ êµ­ì œì  ì¶œì‹œ í™•ëŒ€ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ ë¯¸êµ­ ì‹œì¥ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Net sales growth was 17.5% year-on-year at constant currency. The growth contribution was particularly strong from the ramp-up of Nemluvio, while injectable aesthetics and dermatological skincare grew modestly. Both neuromodulators and fillers and biostimulators outperformed the U.S. market and gained share. Growth was especially driven by Dysport and Sculptra, both growing double digit, while Restylane outperformed a declining filler market. Dysport in the U.S. also benefited from some favorable phasing between the third and fourth quarter. In dermatological skincare, we navigated a constrained consumer spending environment in the U.S., especially impacting Cetaphil.</td><td>ìˆœë§¤ì¶œ ì„±ì¥ë¥ ì€ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ëŒ€ë¹„ 17.5%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì„±ì¥ ê¸°ì—¬ë„ëŠ” íŠ¹íˆ Nemluvioì˜ ë³¸ê²© ì¶œì‹œ(ramp-up)ì—ì„œ ë‘ë“œëŸ¬ì¡Œìœ¼ë©°, ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆê³¼ í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì€ ì™„ë§Œí•œ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œì™€ í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ëª¨ë‘ ë¯¸êµ­ ì‹œì¥ì„ ìƒíšŒí•˜ë©° ì‹œì¥ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ì„±ì¥ì€ íŠ¹íˆ Dysportì™€ Sculptraê°€ ì£¼ë„í–ˆìœ¼ë©°, ë‘ ì œí’ˆ ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. í•œí¸ Restylaneì€ ê°ì†Œì„¸ë¥¼ ë³´ì´ëŠ” í•„ëŸ¬ ì‹œì¥ì—ì„œ ì‹œì¥ ëŒ€ë¹„ ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‚´ DysportëŠ” 3ë¶„ê¸°ì™€ 4ë¶„ê¸° ê°„ ì¼ë¶€ ìœ ë¦¬í•œ ì‹œê¸°ì  ìš”ì¸(favorable phasing)ì˜ í˜œíƒë„ ë°›ì•˜ìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì—ì„œëŠ” ë¯¸êµ­ ë‚´ ì†Œë¹„ì ì§€ì¶œ ìœ„ì¶• í™˜ê²½ì„ í—¤ì³ë‚˜ê°”ìœ¼ë©°, íŠ¹íˆ Cetaphilì´ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nevertheless, Cetaphil in the U.S. saw positive responses made in the third quarter from the multiple... [Technical Difficulty]<br><br>Emil Ivanov<br>Head of Strategy, Investor Relations & ESG<br><br>Apologies for the disruption. We are trying to resume the call, bear with us. Thank you for that. Operator, could you please confirm that the sound is coming through? Operator<br><br>Yes, it is all loud and clear. Emil Ivanov<br>Head of Strategy, Investor Relations & ESG<br><br>Perfect. Thomas will resume his remarks. He is going to resume from his comments related to tariff exposure. Thomas J. Dittrich<br>Chief Financial Officer<br><br>Happy to do that.</td><td>ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³ , ë¯¸êµ­ ë‚´ Cetaphilì€ 3ë¶„ê¸°ì— ë‹¤ì–‘í•œ... [ê¸°ìˆ ì  ë¬¸ì œ]<br><br>Emil Ivanov<br>ì „ëµ, íˆ¬ìì ê´€ê³„ ë° ESG ë‹´ë‹¹ ì±…ì„ì<br><br>ì¤‘ë‹¨ì— ëŒ€í•´ ì‚¬ê³¼ë“œë¦½ë‹ˆë‹¤. ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ì¬ê°œí•˜ë ¤ê³  í•˜ê³  ìˆìœ¼ë‹ˆ ì ì‹œë§Œ ê¸°ë‹¤ë ¤ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. êµí™˜ì›ë‹˜, ìŒì„±ì´ ì œëŒ€ë¡œ ì „ë‹¬ë˜ê³  ìˆëŠ”ì§€ í™•ì¸í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>êµí™˜ì›<br><br>ë„¤, ëª¨ë‘ í¬ê³  ëª…í™•í•˜ê²Œ ë“¤ë¦½ë‹ˆë‹¤.<br><br>Emil Ivanov<br>ì „ëµ, íˆ¬ìì ê´€ê³„ ë° ESG ë‹´ë‹¹ ì±…ì„ì<br><br>ì™„ë²½í•©ë‹ˆë‹¤. Thomasê°€ ë°œì–¸ì„ ì¬ê°œí•˜ê² ìŠµë‹ˆë‹¤. ê´€ì„¸ ë…¸ì¶œê³¼ ê´€ë ¨ëœ ì½”ë©˜íŠ¸ë¶€í„° ë‹¤ì‹œ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Thomas J. Dittrich<br>ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ê¸°êº¼ì´ ê·¸ë ‡ê²Œ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So now moving on to tariff exposure in terms of the U.S., our exposure to tariffs that are already in effect is deemed manageable. Tariffs are mainly relevant for our U.S. fillers and biostimulator portfolio, which represents approximately 7% of our total Galderma net sales. Please recall that any tariff would be on the import value, thus exposing only a portion of the in-market net sales price to tariffs. Furthermore, it is important to remember that our in-market net sales price charge to health care professionals is typically only the smaller portion of the end consumer treatment price. Also recall, more than 90% of all injectable aesthetics products currently sold in the U.S.</td><td>ì´ì œ ë¯¸êµ­ ê´€ì„¸ ë…¸ì¶œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œí–‰ ì¤‘ì¸ ê´€ì„¸ì— ëŒ€í•œ ìš°ë¦¬ì˜ ë…¸ì¶œì€ ê´€ë¦¬ ê°€ëŠ¥í•œ ìˆ˜ì¤€ìœ¼ë¡œ íŒë‹¨ë©ë‹ˆë‹¤. ê´€ì„¸ëŠ” ì£¼ë¡œ ë¯¸êµ­ í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° í¬íŠ¸í´ë¦¬ì˜¤ì™€ ê´€ë ¨ì´ ìˆìœ¼ë©°, ì´ëŠ” Galderma ì „ì²´ ìˆœë§¤ì¶œì˜ ì•½ 7%ë¥¼ ì°¨ì§€í•©ë‹ˆë‹¤. ê´€ì„¸ëŠ” ìˆ˜ì…ê°€ì•¡ì— ë¶€ê³¼ë˜ë¯€ë¡œ, ì‹œì¥ ë‚´ ìˆœë§¤ì¶œ ê°€ê²©ì˜ ì¼ë¶€ë§Œì´ ê´€ì„¸ì— ë…¸ì¶œëœë‹¤ëŠ” ì ì„ ìƒê¸°í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë˜í•œ ì˜ë£Œ ì „ë¬¸ê°€ì—ê²Œ ì²­êµ¬í•˜ëŠ” ìš°ë¦¬ì˜ ì‹œì¥ ë‚´ ìˆœë§¤ì¶œ ê°€ê²©ì€ ì¼ë°˜ì ìœ¼ë¡œ ìµœì¢… ì†Œë¹„ì ì‹œìˆ  ê°€ê²©ì˜ ì‘ì€ ë¶€ë¶„ì— ë¶ˆê³¼í•˜ë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ë˜í•œ í˜„ì¬ ë¯¸êµ­ì—ì„œ íŒë§¤ë˜ëŠ” ì£¼ì‚¬ìš© ë¯¸ìš© ì œí’ˆì˜ 90% ì´ìƒì´</td></tr>
<tr><td>are being imported. Our guidance fully factors in the exposure to all tariffs that are already in effect. Any further tariff announcement will be reviewed as to their potential impact during the remainder of the year, if any. Given the importance of the U.S. market, let me also remind you that we continue to expand our U.S. operations. Earlier this year, we announced our new U.S. headquarters in Miami, Florida, complementing our already established corporate and R&D hubs in 3 other U.S. states. We continue to provide significant health care professional education and training events across the country. We have committed to spend more than USD 650 million on U.S.</td><td>ìˆ˜ì…ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ê°€ì´ë˜ìŠ¤ëŠ” ì´ë¯¸ ì‹œí–‰ ì¤‘ì¸ ëª¨ë“  ê´€ì„¸ì— ëŒ€í•œ ë…¸ì¶œì„ ì™„ì „íˆ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¶”ê°€ ê´€ì„¸ ë°œí‘œê°€ ìˆì„ ê²½ìš°, ì—°ì¤‘ ì”ì—¬ ê¸°ê°„ ë™ì•ˆì˜ ì ì¬ì  ì˜í–¥ì„ ê²€í† í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì˜ ì¤‘ìš”ì„±ì„ ê°ì•ˆí•˜ì—¬, ìš°ë¦¬ê°€ ë¯¸êµ­ ì‚¬ì—…ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. ì˜¬í•´ ì´ˆ, ìš°ë¦¬ëŠ” í”Œë¡œë¦¬ë‹¤ì£¼ ë§ˆì´ì• ë¯¸ì— ìƒˆë¡œìš´ ë¯¸êµ­ ë³¸ì‚¬ë¥¼ ë°œí‘œí–ˆìœ¼ë©°, ì´ëŠ” ì´ë¯¸ ë‹¤ë¥¸ 3ê°œ ì£¼ì— êµ¬ì¶•ëœ ê¸°ì—… ë° R&D í—ˆë¸Œë¥¼ ë³´ì™„í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì „êµ­ì ìœ¼ë¡œ ì˜ë£Œ ì „ë¬¸ê°€ êµìœ¡ ë° í›ˆë ¨ í–‰ì‚¬ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸êµ­ì— 6ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì„ íˆ¬ìí•˜ê¸°ë¡œ ì•½ì†í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>manufacturing activities through the third-party manufacturers over the next 5 years. This includes ramping up final assembly and packaging for Nemluvio in Florida as well as the manufacturing of Alastin and select Cetaphil products with our contract manufacturing partners. Also, Galderma and its partners have initiated additional technology transfers to the U.S. focusing on key growth drivers, including double sourcing Relfydess in the U.S. Now on to guidance. We are raising our guidance for the full year, as Flemming already mentioned. This reflects our strong growth trajectory across the portfolio and especially of Nemluvio.</td><td>í–¥í›„ 5ë…„ê°„ ì œ3ì ì œì¡°ì—…ì²´ë¥¼ í†µí•œ ì œì¡° í™œë™ì„ ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” í”Œë¡œë¦¬ë‹¤ì—ì„œ Nemluvioì˜ ìµœì¢… ì¡°ë¦½ ë° í¬ì¥ í™•ëŒ€, ê·¸ë¦¬ê³  ê³„ì•½ ì œì¡° íŒŒíŠ¸ë„ˆì‚¬ë“¤ê³¼ í•¨ê»˜í•˜ëŠ” Alastin ë° ì¼ë¶€ Cetaphil ì œí’ˆì˜ ì œì¡°ê°€ í¬í•¨ë©ë‹ˆë‹¤. ë˜í•œ Galdermaì™€ íŒŒíŠ¸ë„ˆì‚¬ë“¤ì€ Relfydessì˜ ë¯¸êµ­ ë‚´ ì´ì¤‘ ê³µê¸‰ë§ êµ¬ì¶•ì„ í¬í•¨í•œ í•µì‹¬ ì„±ì¥ ë™ë ¥ì— ì´ˆì ì„ ë§ì¶° ë¯¸êµ­ìœ¼ë¡œì˜ ì¶”ê°€ ê¸°ìˆ  ì´ì „ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ì œ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Flemmingì´ ì´ë¯¸ ì–¸ê¸‰í–ˆë“¯ì´, ë‹¹ì‚¬ëŠ” ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒí–¥ ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜, íŠ¹íˆ Nemluvioì˜ ê°•ë ¥í•œ ì„±ì¥ ê¶¤ë„ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We are raising net sales to 17.0% to 17.7% year-on-year growth at constant currency from previously 12% to 14%. On core EBITDA, we are raising the margin range to 23.1% to 23.6% at constant currency from previously approximately 23%. The guidance update especially reflects the significant ramp-up of Nemluvio which is driving growth in therapeutic dermatology. It also reflects the strong trajectory in injectable aesthetics with continued outperformance of the market in both neuromodulators and fillers and biostimulators. In neuromodulators, the fourth quarter is expected to be impacted by phasing effects.</td><td>ì €í¬ëŠ” ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ê¸°ì¡´ 12~14%ì—ì„œ ìƒí–¥ ì¡°ì •í•˜ì—¬ ìƒìˆ˜í™˜ìœ¨ ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 17.0~17.7% ì„±ì¥ìœ¼ë¡œ ìƒí–¥í•©ë‹ˆë‹¤. í•µì‹¬ EBITDA ë§ˆì§„ì€ ê¸°ì¡´ ì•½ 23%ì—ì„œ ìƒìˆ˜í™˜ìœ¨ ê¸°ì¤€ 23.1~23.6%ë¡œ ìƒí–¥ ì¡°ì •í•©ë‹ˆë‹¤. ì´ë²ˆ ê°€ì´ë˜ìŠ¤ ìƒí–¥ ì¡°ì •ì€ íŠ¹íˆ ì¹˜ë£Œìš© í”¼ë¶€ê³¼ ë¶€ë¬¸ì˜ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆëŠ” ë„´ë£¨ë¹„ì˜¤(Nemluvio)ì˜ ì˜ë¯¸ ìˆëŠ” ë§¤ì¶œ í™•ëŒ€ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì‹ ê²½ì¡°ì ˆì œì™€ í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ëª¨ë‘ì—ì„œ ì‹œì¥ ëŒ€ë¹„ ì§€ì†ì ì¸ ì´ˆê³¼ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆëŠ” ì£¼ì‚¬ìš© ë¯¸ìš© ì œí’ˆì˜ ê°•ë ¥í•œ ì„±ì¥ ê¶¤ì ë„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œì˜ ê²½ìš°, 4ë¶„ê¸°ëŠ” ì‹œê¸°ì  íš¨ê³¼ì˜ ì˜í–¥ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Full year net sales growth for neuromodulators is expected to be in the low teens at constant currency. At the half year call, I translated low teens at 11% to 13%, as you recall. As we have now delivered a strong third quarter growth rate, our full year performance is largely derisked, and we expect growth towards the upper end of this 11% to 13% growth range. In fillers and biostimulators, expectations for the fourth quarter are to maintain the recent growth momentum based on the strong trajectory of Sculptra, and from new launches. Dermatological skincare is expected to accelerate its growth momentum to reach high single-digit growth at constant currency for the full year.</td><td>ì‹ ê²½ì¡°ì ˆì œì˜ ì—°ê°„ ìˆœë§¤ì¶œ ì„±ì¥ë¥ ì€ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ low teens(10%ëŒ€ ì´ˆë°˜)ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë°˜ê¸° ì‹¤ì  ë°œí‘œì—ì„œ ë§ì”€ë“œë ¸ë“¯ì´, ì €ëŠ” low teensë¥¼ 11%ì—ì„œ 13%ë¡œ í•´ì„í–ˆìŠµë‹ˆë‹¤. ì´ì œ 3ë¶„ê¸°ì— ê°•ë ¥í•œ ì„±ì¥ë¥ ì„ ë‹¬ì„±í–ˆê¸° ë•Œë¬¸ì—, ì—°ê°„ ì‹¤ì ì˜ ë¶ˆí™•ì‹¤ì„±ì€ ëŒ€ë¶€ë¶„ í•´ì†Œë˜ì—ˆìœ¼ë©°, ì´ 11%ì—ì„œ 13% ì„±ì¥ ë²”ìœ„ì˜ ìƒë‹¨ ìª½ìœ¼ë¡œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í•„ëŸ¬ ë° ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ë¶€ë¬¸ì˜ 4ë¶„ê¸° ì „ë§ì€ ìŠ¤ì»¬íŠ¸ë¼(Sculptra)ì˜ ê°•ë ¥í•œ ì„±ì¥ì„¸ì™€ ì‹ ì œí’ˆ ì¶œì‹œë¥¼ ë°”íƒ•ìœ¼ë¡œ ìµœê·¼ì˜ ì„±ì¥ ëª¨ë©˜í…€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì€ ì„±ì¥ ëª¨ë©˜í…€ì´ ê°€ì†í™”ë˜ì–´ ê³ ì •í™˜ìœ¨ ê¸°ì¤€ ì—°ê°„ high single-digit(í•œ ìë¦¿ìˆ˜ í›„ë°˜) ì„±ì¥ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>And finally, for the therapeutic dermatology mature portfolio, the Q3 year-to-date performance is indicative of our expected full year growth for this part of the business. The updated core EBITDA margin reflects reinvestments into growth for the group and to support Nemluvio's strong ramp-up. It also factors in the exposure to all U.S. tariffs that are currently in effect. Any further tariff announcements will be reviewed as to their potential impact during the remainder of the year. Please note that the updated guidance also has implications on the additional modeling metrics, which were previously provided in the financial results.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, ì„±ìˆ™ê¸° ì¹˜ë£Œ í”¼ë¶€ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ì˜ 3ë¶„ê¸° ëˆ„ì  ì‹¤ì ì€ ì´ ì‚¬ì—… ë¶€ë¬¸ì˜ ì˜ˆìƒ ì—°ê°„ ì„±ì¥ë¥ ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì—…ë°ì´íŠ¸ëœ í•µì‹¬ EBITDA ë§ˆì§„ì€ ê·¸ë£¹ì˜ ì„±ì¥ì„ ìœ„í•œ ì¬íˆ¬ìì™€ Nemluvioì˜ ê°•ë ¥í•œ í™•ëŒ€ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ íˆ¬ìë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. ë˜í•œ í˜„ì¬ ì‹œí–‰ ì¤‘ì¸ ëª¨ë“  ë¯¸êµ­ ê´€ì„¸ì— ëŒ€í•œ ë…¸ì¶œë„ ê³ ë ¤ë˜ì—ˆìŠµë‹ˆë‹¤. ì¶”ê°€ ê´€ì„¸ ë°œí‘œê°€ ìˆì„ ê²½ìš°, ì—°ë‚´ ì ì¬ì  ì˜í–¥ì— ëŒ€í•´ ê²€í† í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì—…ë°ì´íŠ¸ëœ ê°€ì´ë˜ìŠ¤ëŠ” ì´ì „ ì¬ë¬´ ì‹¤ì ì—ì„œ ì œê³µëœ ì¶”ê°€ ëª¨ë¸ë§ ì§€í‘œì—ë„ ì˜í–¥ì„ ë¯¸ì¹œë‹¤ëŠ” ì ì„ ìœ ë…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>In particular, the increased profitability is expected to positively impact the effective tax rate for the full year, putting it towards the lower end of the previously provided 23% to 25% range that we have provided at the half year call. This concludes the introductory remarks of Galderma's trading update for the third quarter of 2025. Before we close the meeting with Flemming's final remarks, I would like to now hand back to the operator to open the call for questions. [Operator Instructions]<br><br>Operator, can you please now open the line?</td><td>íŠ¹íˆ, ì¦ê°€í•œ ìˆ˜ìµì„±ì€ ì—°ê°„ ì‹¤íš¨ì„¸ìœ¨ì— ê¸ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ë°˜ê¸° ì‹¤ì  ë°œí‘œì—ì„œ ì œì‹œí–ˆë˜ 23%ì—ì„œ 25% ë²”ìœ„ì˜ í•˜ë‹¨ ìª½ì— ìœ„ì¹˜í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ Galdermaì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ì—…ë°ì´íŠ¸ì— ëŒ€í•œ ë„ì… ë°œì–¸ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. Flemmingì˜ ë§ˆë¬´ë¦¬ ë°œì–¸ìœ¼ë¡œ íšŒì˜ë¥¼ ì¢…ë£Œí•˜ê¸° ì „ì—, ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ìœ„í•´ ë‹¤ì‹œ êµí™˜ì›ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. [êµí™˜ì› ì•ˆë‚´ì‚¬í•­]<br><br>êµí™˜ì›ë‹˜, ì´ì œ íšŒì„ ì„ ì—´ì–´ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Galderma Q3 2025 ì‹¤ì  ìš”ì•½<br><br>â€¢ **ë§¤ì¶œ ì„±ì¥ ê°€ì†í™” ë° ê°€ì´ë˜ìŠ¤ ìƒí–¥**: 9ê°œì›” ëˆ„ì  ë§¤ì¶œ 37ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 15% ì„±ì¥(ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€), 3ë¶„ê¸°ëŠ” 21% ì„±ì¥ìœ¼ë¡œ ê°€ì†í™”. ì „ ì œí’ˆêµ°ê³¼ ì§€ì—­ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ ë‹¬ì„±. ì—°ê°„ ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ê¸°ì¡´ 12~14%ì—ì„œ 17.0~17.7%ë¡œ ëŒ€í­ ìƒí–¥ ì¡°ì •í•˜ê³ , Core EBITDA ë§ˆì§„ë„ ì•½ 23%ì—ì„œ 23.1~23.6%ë¡œ ìƒí–¥.<br><br>â€¢ **Nemluvioì˜ ì˜ˆìƒ ì´ˆê³¼ ì„±ê³¼ê°€ í•µì‹¬ ë™ë ¥**: ì¹˜ë£Œ í”¼ë¶€ê³¼ ë¶€ë¬¸ì´ 40.4% ì„±ì¥í•˜ë©° Nemluvioê°€ ì£¼ìš” ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ë¶€ìƒ. ë¯¸êµ­ì—ì„œ ì•„í† í”¼ í”¼ë¶€ì—¼ ë§¤ì¶œì´ 3ë¶„ê¸° ì²˜ìŒìœ¼ë¡œ ê²°ì ˆì„± ê°€ë ¤ì›€ì¦ì„ ì´ˆê³¼í–ˆìœ¼ë©°, ìƒì—…ë³´í—˜ ì»¤ë²„ë¦¬ì§€ê°€ 80% ì´ìƒ í™•ëŒ€. ì‹ ê·œ í™˜ìì˜ ëŒ€ë‹¤ìˆ˜ê°€ ê³ ê¸‰ ì¹˜ë£Œì œ ë¯¸ê²½í—˜ìë¡œ, ì‹œì¥ ì¹¨íˆ¬ë ¥ ì…ì¦.<br><br>â€¢ **ì£¼ì‚¬ì œ ë¯¸ìš© ë¶€ë¬¸ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€**: ì‹ ê²½ì¡°ì ˆì œ(14% ì„±ì¥)ì™€ í•„ëŸ¬/ë°”ì´ì˜¤ìê·¹ì œ(6.2% ì„±ì¥) ëª¨ë‘ ì‹œì¥ ì„±ì¥ë¥  ìƒíšŒ. Relfydessì˜ 17ê°œ ì‹œì¥ ì¶œì‹œ ì„±ê³µê³¼ Sculptraì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥(íŠ¹íˆ ì¤‘êµ­ ì‹ ê·œ ì¶œì‹œ)ì´ ê¸°ì—¬. 3ë¶„ê¸° ì‹ ê²½ì¡°</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] And now we're going to take our first question. And it comes to the line of Thibault Boutherin from Morgan Stanley.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì´ì œ ì²« ë²ˆì§¸ ì§ˆë¬¸ì„ ë°›ê² ìŠµë‹ˆë‹¤. ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í‹°ë³´ ë¶€í…Œë­ë‹˜ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Thibault Boutherin: Morgan Stanley, Research Division A question is just on Nemluvio for the rest of the year. When we triangulate your comments on the business trends in Q4, it's clear to us that Nemluvio is the biggest moving part in the guidance. So if you could just tell us where you see the most viability here, is it the uptake in atopic dermatitis in the U.S.? Is it the excess uptake? Any sort of help you can give us on where you see the moving parts for Nemluvio in Q4 would be helpful.</td><td>**Thibault Boutherin:** ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆì˜ ë„´ë£¨ë¹„ì˜¤ì— ëŒ€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. 4ë¶„ê¸° ì‚¬ì—… ë™í–¥ì— ëŒ€í•œ ê·€ì‚¬ì˜ ì½”ë©˜íŠ¸ë¥¼ ì¢…í•©í•´ë³´ë©´, ë„´ë£¨ë¹„ì˜¤ê°€ ê°€ì´ë˜ìŠ¤ì—ì„œ ê°€ì¥ í° ë³€ë™ ìš”ì¸ì´ë¼ëŠ” ê²ƒì´ ëª…í™•í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì—¬ê¸°ì„œ ê°€ì¥ í° ê°€ëŠ¥ì„±ì„ ì–´ë””ì—ì„œ ë³´ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ë¯¸êµ­ ë‚´ ì•„í† í”¼ í”¼ë¶€ì—¼ì—ì„œì˜ ì²˜ë°© ì¦ê°€ì¸ê°€ìš”? ì•„ë‹ˆë©´ ì´ˆê³¼ ìˆ˜ìš”ì¸ê°€ìš”? 4ë¶„ê¸° ë„´ë£¨ë¹„ì˜¤ì˜ ë³€ë™ ìš”ì¸ì„ ì–´ë””ì—ì„œ ë³´ê³  ê³„ì‹ ì§€ ì–´ë–¤ ë„ì›€ì´ë¼ë„ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. I don't know if I agree with your analytics, First of all, thanks for the question. It's USD 263 million so far. You can see we have reported USD 3.737 billion. If I can do the math, that's not the majority. We had double-digit growth in injectable aesthetics. We have double-digit growth in therapeutic dermatology. We had 8.2% growth in dermatological skincare. So I think we have to be a little bit careful not to think that this is about Nemluvio. Nemluvio is in a very early stage of its trajectory. It's performing or outperforming any benchmark we've set. We're at 7.2%, I think, share at this stage. If you look at NBRx for the AD market, and we're at 37%, if you look at PN, we are now north of 80% commercial coverage and next year, we'll enter most likely into the Medicare and Medicaid. But we have a lot of other things that are growing incredibly fast, and Nemluvio is important, but it's not the only thing. And if I think about the contributions of Cetaphil international. If I think about the contribution already of Relfydess, if I see the very strong performance of Dysport around the world, I think it was a little bit -- we need to moderate that sentiment.</td><td>**CEO & Director:** ë„¤, ê·€í•˜ì˜ ë¶„ì„ì— ë™ì˜í•˜ëŠ”ì§€ëŠ” ëª¨ë¥´ê² ìŠµë‹ˆë‹¤. ìš°ì„  ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. í˜„ì¬ê¹Œì§€ 2ì–µ 6,300ë§Œ ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì €í¬ê°€ ë³´ê³ í•œ ê¸ˆì•¡ì€ 37ì–µ 3,700ë§Œ ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ì œ ê³„ì‚°ì´ ë§ë‹¤ë©´, ì´ê±´ ê³¼ë°˜ì´ ì•„ë‹™ë‹ˆë‹¤. ì£¼ì‚¬í˜• ë¯¸ìš© ë¶€ë¬¸ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆê³ , ì¹˜ë£Œ í”¼ë¶€ê³¼ ë¶€ë¬¸ì—ì„œë„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ ìŠ¤í‚¨ì¼€ì–´ ë¶€ë¬¸ì€ 8.2% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ë„´ë£¨ë¹„ì˜¤ë§Œì˜ ì„±ê³¼ë¼ê³  ìƒê°í•˜ì§€ ì•Šë„ë¡ ì¡°ê¸ˆ ì£¼ì˜í•  í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤ëŠ” ì•„ì§ ì„±ì¥ ê¶¤ë„ì˜ ë§¤ìš° ì´ˆê¸° ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì„¤ì •í•œ ëª¨ë“  ë²¤ì¹˜ë§ˆí¬ë¥¼ ë‹¬ì„±í•˜ê±°ë‚˜ ì´ˆê³¼ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ ë‹¨ê³„ì—ì„œ ì‹œì¥ì ìœ ìœ¨ 7.2%ë¥¼ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. AD ì‹œì¥ì˜ NBRxë¥¼ ë³´ì‹œë©´ ì €í¬ê°€ 37%ë¥¼ ì°¨ì§€í•˜ê³  ìˆê³ , PNì˜ ê²½ìš° í˜„ì¬ ìƒì—… ë³´í—˜ ì»¤ë²„ë¦¬ì§€ê°€ 80%ë¥¼ ë„˜ì–´ì„°ìœ¼ë©° ë‚´ë…„ì—ëŠ” ë©”ë””ì¼€ì–´ì™€ ë©”ë””ì¼€ì´ë“œì—ë„ ì§„ì…í•  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ì—ê²ŒëŠ” ë§¤ìš° ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê³  ìˆëŠ” ë‹¤ë¥¸ ë§ì€ ì œí’ˆë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤ê°€ ì¤‘ìš”í•œ ê²ƒì€ ë§ì§€ë§Œ, ê·¸ê²ƒì´ ì „ë¶€ëŠ” ì•„ë‹™ë‹ˆë‹¤. ì„¸íƒ€í•„ ì¸í„°ë‚´ì…”ë„ì˜ ê¸°ì—¬ë„ë¥¼ ìƒê°í•´ë³´ë©´, ì´ë¯¸ ë íŒŒì´ë°ìŠ¤ì˜ ê¸°ì—¬ë„ë¥¼ ìƒê°í•´ë³´ë©´, ì „ ì„¸ê³„ì ìœ¼ë¡œ ë””ìŠ¤í¬íŠ¸ì˜ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì„ ë³´ë©´, ê·¸ëŸ° ìš°ë ¤ëŠ” ì¡°ê¸ˆ ê³¼í•œ ë©´ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ëŸ° ê°ì •ì€ ì™„í™”í•  í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Any further questions, Thibault?</td><td>**Operator:** ì¶”ê°€ ì§ˆë¬¸ ìˆìœ¼ì‹ ê°€ìš”, í‹°ë³´?</td></tr>
<tr><td>Thibault Boutherin: Morgan Stanley, Research Division Yes. No. I mean, I think the question was just on the moving parts in Q4 in particular, but that's fine. Thank you.</td><td>**Thibault Boutherin:** ë„¤, ì•„ë‹™ë‹ˆë‹¤. ì œ ì§ˆë¬¸ì€ íŠ¹íˆ 4ë¶„ê¸°ì˜ ë³€ë™ ìš”ì¸ë“¤ì— ëŒ€í•œ ê²ƒì´ì—ˆëŠ”ë°, ê´œì°®ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. We don't manage the company with just one compound. We have -- we ship the resources. And I think we've seen -- we have brought growth in international and in the U.S., 17.5% growth in the U.S. 12-plus percent in international. And if you look at the portfolio, it's almost all products that are showing incredibly strong growth, not just Nemluvio.</td><td>**CEO & Director:** ë„¤, ì €í¬ëŠ” ë‹¨ì¼ ì œí’ˆë§Œìœ¼ë¡œ íšŒì‚¬ë¥¼ ìš´ì˜í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë¦¬ì†ŒìŠ¤ë¥¼ ì ì ˆíˆ ë°°ë¶„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ë¯¸êµ­ì—ì„œ 17.5%, í•´ì™¸ì—ì„œ 12% ì´ìƒì˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ì‹œë©´ ë„´ë£¨ë¹„ì˜¤ë¿ë§Œ ì•„ë‹ˆë¼ ê±°ì˜ ëª¨ë“  ì œí’ˆë“¤ì´ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And the question comes line of Harry Sefton from UBS.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì§ˆë¬¸ì€ UBSì˜ Harry Seftonìœ¼ë¡œë¶€í„° ë“¤ì–´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Harry Sefton: So in fillers and biostimulators, we saw another strong quarter against the backdrop of a weak, HA filler market. Should we think about the vast majority of that growth being driven by Sculptra? And how should we think about the growth going into 2026 for Sculptra given the push into GLP-1 patients do you think you'll be able to accelerate the growth of Sculptra next year? And then also thinking about Restylane growth going into next year given the launch of skin boosters in the U.S., and a couple of other SKUs?</td><td>**Harry Sefton:** í•„ëŸ¬ì™€ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ë¶€ë¬¸ì—ì„œ HA í•„ëŸ¬ ì‹œì¥ì´ ì•½ì„¸ë¥¼ ë³´ì´ëŠ” ê°€ìš´ë° ë˜ í•œ ë²ˆ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ê±°ë’€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì˜ ëŒ€ë¶€ë¶„ì´ ìŠ¤ì»¬íŠ¸ë¼(Sculptra)ì—ì„œ ë‚˜ì˜¨ ê²ƒìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  GLP-1 í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ê³µëµì„ ê³ ë ¤í•  ë•Œ, 2026ë…„ ìŠ¤ì»¬íŠ¸ë¼ ì„±ì¥ì„ ì–´ë–»ê²Œ ì „ë§í•´ì•¼ í• ê¹Œìš”? ë‚´ë…„ì— ìŠ¤ì»¬íŠ¸ë¼ì˜ ì„±ì¥ì„ ë”ìš± ê°€ì†í™”í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ìš”? ë˜í•œ ë¯¸êµ­ ë‚´ ìŠ¤í‚¨ë¶€ìŠ¤í„° ì¶œì‹œì™€ ëª‡ ê°€ì§€ ë‹¤ë¥¸ SKUë“¤ì„ ê°ì•ˆí•  ë•Œ, ë‚´ë…„ ë ˆìŠ¤í‹¸ë Œ(Restylane) ì„±ì¥ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: No, a very insightful question. Thanks very much. Yes, sometimes one get lost in the minutia details. If you take a step back, your strategic comment is totally right. Over time, in the combined category of fillers and biostimulators. Sculptra, the biostimulator part is approaching half and will probably overtake it sometime next year. What we are seeing, but these are early signs. You should talk to all our competition. Is there a flattening on the negative trend with fillers, yes or no, your insights may be as good as ours. What we are seeing is that if you launch new and innovative fillers like what we've seen with Restylane SHAYPE, we have uptakes that matches some of the best launches like Restylane Kysse, Restylane Lift, we've had -- so I think it's a bit of a mixed bag. There's pricing pressure. There's commoditization. But if you bring innovation to the market, you see that the unique advantage for us in one of the largest markets, we're going to be launching, I think, up to 6 new products, several of them being fillers next year. In the U.S., if all goes well. We are in the final stage of regulatory approvals for those. So that should give us a boost. But it is quite clear that the trend among consumers is yes, we all want a neuromodulator and now we also want a biostimulatory product. And then we add on a filler. But for treatment of some of the effects of significant weight loss with GLP-1s, you will need both a filler ad biostimulatory product. It's early days to say -- our growth is driving in certain parts of the world, if you go to the Middle East, it's a significant part, in the U.S., it's still early days.</td><td>**CEO & Director:** ë§¤ìš° í†µì°°ë ¥ ìˆëŠ” ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë„¤, ë•Œë¡œëŠ” ì„¸ë¶€ì‚¬í•­ì— ë§¤ëª°ë˜ê¸° ì‰½ì£ . í•œ ë°œì§ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, ë§ì”€í•˜ì‹  ì „ëµì  ê´€ì ì´ ì™„ì „íˆ ë§ìŠµë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ í•„ëŸ¬ì™€ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„°ë¥¼ í•©ì¹œ ì¹´í…Œê³ ë¦¬ì—ì„œ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„°ì¸ ìŠ¤ì»¬íŠ¸ë¼ ë¶€ë¬¸ì´ ì ˆë°˜ì— ê°€ê¹Œì›Œì§€ê³  ìˆìœ¼ë©°, ì•„ë§ˆë„ ë‚´ë…„ ì–´ëŠ ì‹œì ì—ëŠ” ì´ë¥¼ ë„˜ì–´ì„¤ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. <br><br>ì§€ê¸ˆ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ ì´ˆê¸° ì‹ í˜¸ë“¤ì…ë‹ˆë‹¤ë§Œ, ê²½ìŸì‚¬ë“¤ê³¼ë„ ì´ì•¼ê¸°ë¥¼ ë‚˜ëˆ ë³´ì‹œë©´ ì¢‹ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. í•„ëŸ¬ì˜ í•˜ë½ ì¶”ì„¸ê°€ ì™„í™”ë˜ê³  ìˆëŠ”ì§€ ì—¬ë¶€ì— ëŒ€í•´ì„œëŠ” ì—¬ëŸ¬ë¶„ì˜ ì¸ì‚¬ì´íŠ¸ë„ ìš°ë¦¬ë§Œí¼ ì •í™•í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ í™•ì¸í•˜ê³  ìˆëŠ” ê²ƒì€ ë ˆìŠ¤í‹¸ë Œ ì‰ì…(Restylane SHAYPE)ì²˜ëŸ¼ ìƒˆë¡­ê³  í˜ì‹ ì ì¸ í•„ëŸ¬ë¥¼ ì¶œì‹œí•˜ë©´, ë ˆìŠ¤í‹¸ë Œ í‚¤ì„¸(Restylane Kysse), ë ˆìŠ¤í‹¸ë Œ ë¦¬í”„íŠ¸(Restylane Lift) ê°™ì€ ìµœê³ ì˜ ì¶œì‹œ ì‚¬ë¡€ë“¤ê³¼ ë§ë¨¹ëŠ” ìˆ˜ì¤€ì˜ ì‹œì¥ ë°˜ì‘ì„ ì–»ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë‹¤ì†Œ í˜¼ì¬ëœ ì–‘ìƒì´ë¼ê³  ë´…ë‹ˆë‹¤. ê°€ê²© ì••ë°•ê³¼ ìƒí’ˆí™” í˜„ìƒì´ ìˆëŠ” ê²ƒì€ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹œì¥ì— í˜ì‹ ì„ ê°€ì ¸ì˜¨ë‹¤ë©´ ìƒí™©ì€ ë‹¬ë¼ì§‘ë‹ˆë‹¤. ê°€ì¥ í° ì‹œì¥ ì¤‘ í•˜ë‚˜ì—ì„œ ìš°ë¦¬ê°€ ê°€ì§„ ë…íŠ¹í•œ ì´ì ì„ ë³´ì‹œë©´, ë‚´ë…„ì— ë¯¸êµ­ì—ì„œ ìµœëŒ€ 6ê°œì˜ ì‹ ì œí’ˆì„ ì¶œì‹œí•  ì˜ˆì •ì¸ë°, ê·¸ ì¤‘ ì—¬ëŸ¬ ì œí’ˆì´ í•„ëŸ¬ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ëª¨ë“  ê²ƒì´ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ëœë‹¤ë©´ ë§ì´ì£ . í˜„ì¬ ìµœì¢… ê·œì œ ìŠ¹ì¸ ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ì—ê²Œ í° í˜ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ ì†Œë¹„ìë“¤ ì‚¬ì´ì˜ íŠ¸ë Œë“œëŠ” ë§¤ìš° ëª…í™•í•©ë‹ˆë‹¤. ëª¨ë‘ê°€ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator)ë¥¼ ì›í•˜ê³ , ì´ì œëŠ” ìƒì²´ìê·¹(biostimulatory) ì œí’ˆë„ ì›í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì— í•„ëŸ¬ë¥¼ ì¶”ê°€í•˜ëŠ” ê²ƒì´ì£ . íŠ¹íˆ GLP-1 ì•½ë¬¼ë¡œ ì¸í•œ ìƒë‹¹í•œ ì²´ì¤‘ ê°ì†Œì˜ ë¶€ì‘ìš©ì„ ì¹˜ë£Œí•˜ê¸° ìœ„í•´ì„œëŠ” í•„ëŸ¬ì™€ ìƒì²´ìê·¹ ì œí’ˆ ëª¨ë‘ê°€ í•„ìš”í•  ê²ƒì…ë‹ˆë‹¤. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ”ë°ìš”, ì €í¬ ì„±ì¥ì€ ì„¸ê³„ íŠ¹ì • ì§€ì—­ì—ì„œ ê²¬ì¸ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘ë™ ì§€ì—­ìœ¼ë¡œ ê°€ë©´ ìƒë‹¹í•œ ë¹„ì¤‘ì„ ì°¨ì§€í•˜ê³  ìˆê³ , ë¯¸êµ­ì—ì„œëŠ” ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: And then I would only add when you -- and you asked about '26, and we're not going to comment on '26, Harry. But on the longer-term, when you think about the biostimulator opportunity, remember, we just launched in China and the biostimulator opportunity longer-term in China is so big. It's bigger than most -- the sizes of most injectable aesthetics markets in JPAC. So that's why we just start -- launched and then together with Flemming's comments, think of the longer-term secular trend that we have here, and that's really big and amazing.</td><td>**Chief Financial Officer:** ê·¸ë¦¬ê³  í•œ ê°€ì§€ë§Œ ë§ë¶™ì´ìë©´, 26ë…„ë„ì— ëŒ€í•´ ì§ˆë¬¸í•˜ì…¨ëŠ”ë°, 26ë…„ë„ì— ëŒ€í•´ì„œëŠ” ì–¸ê¸‰í•˜ì§€ ì•Šê² ìŠµë‹ˆë‹¤, Harry. í•˜ì§€ë§Œ ì¥ê¸°ì  ê´€ì ì—ì„œ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„°(biostimulator) ê¸°íšŒë¥¼ ìƒê°í•´ë³´ì‹œë©´, ì¤‘êµ­ì—ì„œ ì´ì œ ë§‰ ì¶œì‹œí–ˆë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ì…”ì•¼ í•©ë‹ˆë‹¤. ì¤‘êµ­ì—ì„œì˜ ë°”ì´ì˜¤ìŠ¤í‹°ë®¬ë ˆì´í„° ì¥ê¸° ê¸°íšŒëŠ” ì •ë§ í½ë‹ˆë‹¤. JPAC ì§€ì—­ ëŒ€ë¶€ë¶„ì˜ ì£¼ì‚¬í˜• ë¯¸ìš© ì‹œì¥ ê·œëª¨ë³´ë‹¤ ë” í½ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ì œ ë§‰ ì¶œì‹œë¥¼ ì‹œì‘í•œ ê²ƒì´ê³ , Flemmingì´ ì–¸ê¸‰í•œ ë‚´ìš©ê³¼ í•¨ê»˜ ìš°ë¦¬ê°€ ê°€ì§„ ì¥ê¸°ì ì¸ êµ¬ì¡°ì  ì„±ì¥ íŠ¸ë Œë“œë¥¼ ìƒê°í•´ë³´ì‹œë©´, ì •ë§ í¬ê³  ë†€ë¼ìš´ ê¸°íšŒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And the next question comes from the line of Shyam Kotadia from Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Goldman Sachsì˜ Shyam Kotadiaë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Shyam Kotadia: Goldman Sachs Group, Inc., Research Division A quick one on Nemluvio. So in terms of the guidance going forward, you mentioned in the prior results that you're going to consider your greater than $2 billion peak sales guide for the drug. So given the ramp continues to be strong, do you have any update from that perspective? And also any update in terms of the breakeven assumptions, which I believe previously were 2027 and also your assumption to hit blockbuster run rate was also 2027. So any update in regards to that would be super helpful.</td><td>**Shyam Kotadia:** ë„´ë£¨ë¹„ì˜¤ì— ëŒ€í•´ ê°„ë‹¨íˆ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í–¥í›„ ê°€ì´ë˜ìŠ¤ ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ì´ì „ ì‹¤ì  ë°œí‘œì—ì„œ ì´ ì•½ë¬¼ì˜ í”¼í¬ ë§¤ì¶œ 20ì–µ ë‹¬ëŸ¬ ì´ìƒ ê°€ì´ë˜ìŠ¤ë¥¼ ê²€í† í•˜ì‹¤ ê²ƒì´ë¼ê³  ì–¸ê¸‰í•˜ì…¨ìŠµë‹ˆë‹¤. ìƒìŠ¹ì„¸ê°€ ê³„ì† ê°•í•˜ê²Œ ìœ ì§€ë˜ê³  ìˆëŠ” ìƒí™©ì—ì„œ, ì´ ë¶€ë¶„ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ê°€ ìˆìœ¼ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì†ìµë¶„ê¸°ì (breakeven) ê°€ì •ê³¼ ê´€ë ¨í•´ì„œë„ ì—…ë°ì´íŠ¸ê°€ ìˆìœ¼ì‹ ì§€ìš”. ì œ ê¸°ì–µìœ¼ë¡œëŠ” ì´ì „ì— 2027ë…„ìœ¼ë¡œ ì˜ˆìƒí•˜ì…¨ê³ , ë¸”ë¡ë²„ìŠ¤í„° ëŸ°ë ˆì´íŠ¸(blockbuster run rate) ë‹¬ì„± ì‹œì ë„ 2027ë…„ìœ¼ë¡œ ê°€ì •í•˜ì…¨ë˜ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ì™€ ê´€ë ¨í•˜ì—¬ ì—…ë°ì´íŠ¸í•´ ì£¼ì‹œë©´ ì •ë§ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. I don't think at this stage, we're going to give guidance on Nemluvio apart from what we've already said, it's $2 billion plus. When we look at the data, the uptake continues to be very strong. I think part of the success with the launch so far is we keep the head to the ground, and we focus on building out the sales force, making sure we get access, making sure we do well against that very tough competitive set and that we get as many doctors to experience the product so that they also can prescribe it to more patients. The -- there's a lot of change going on. We used to be mainly dependent on PN. Now we see that AD is a larger part in the third quarter. That was the largest part. So net-net, of course, with this strong uptick, if it continues to that way, we will, at some point, consider resetting the guidance for peak sales and, of course, also the profitability threshold guidance.</td><td>**CEO & Director:** ë„¤, í˜„ ë‹¨ê³„ì—ì„œëŠ” ì´ë¯¸ ë§ì”€ë“œë¦° 20ì–µ ë‹¬ëŸ¬ ì´ìƒì´ë¼ëŠ” ê²ƒ ì™¸ì— ë„´ë£¨ë¹„ì˜¤ì— ëŒ€í•œ ì¶”ê°€ ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•˜ì§€ëŠ” ì•Šì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë°ì´í„°ë¥¼ ë³´ë©´ ìˆ˜ìš” ì¦ê°€ì„¸ê°€ ë§¤ìš° ê°•ë ¥í•˜ê²Œ ì§€ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ì¶œì‹œê°€ ì„±ê³µì ì´ì—ˆë˜ ì´ìœ  ì¤‘ í•˜ë‚˜ëŠ” ìš°ë¦¬ê°€ í˜„ì¥ì— ì§‘ì¤‘í•˜ë©´ì„œ ì˜ì—… ì¡°ì§ì„ êµ¬ì¶•í•˜ê³ , ì‹œì¥ ì ‘ê·¼ì„±ì„ í™•ë³´í•˜ë©°, ë§¤ìš° ì¹˜ì—´í•œ ê²½ìŸ í™˜ê²½ì—ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³ , ê°€ëŠ¥í•œ í•œ ë§ì€ ì˜ì‚¬ë“¤ì´ ì œí’ˆì„ ê²½í—˜í•˜ì—¬ ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ì²˜ë°©í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë° ì£¼ë ¥í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë§ì€ ë³€í™”ê°€ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê³¼ê±°ì—ëŠ” ì£¼ë¡œ PN(ê²°ì ˆì„± ì–‘ì§„)ì— ì˜ì¡´í–ˆì§€ë§Œ, ì´ì œëŠ” 3ë¶„ê¸°ì— AD(ì•„í† í”¼ í”¼ë¶€ì—¼)ê°€ ë” í° ë¹„ì¤‘ì„ ì°¨ì§€í–ˆê³ , ì‹¤ì œë¡œ ê°€ì¥ í° ë¶€ë¶„ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. <response><br><br>ê²°ë¡ ì ìœ¼ë¡œ, ì´ëŸ¬í•œ ê°•ë ¥í•œ ìƒìŠ¹ì„¸ê°€ ê³„ì†ëœë‹¤ë©´, ì ì ˆí•œ ì‹œì ì— ìµœê³  ë§¤ì¶œ(peak sales) ê°€ì´ë˜ìŠ¤ì™€ ìˆ˜ìµì„± ê¸°ì¤€ì (profitability threshold) ê°€ì´ë˜ìŠ¤ë¥¼ ì¬ì¡°ì •í•˜ëŠ” ê²ƒì„ ê²€í† í•  ê²ƒì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Chief Financial Officer: Yes. And on the profitability, I mean, let me just comment there on 2025 because this is the Q3 2025 call. Recall that we said that we expected in the H1 call we expected the adverse P&L impact from Nemluvio launch investments and other investments to be 60% in H1 and 40% in H2. Let me update that here with by saying that in H1, we have seen 75% of the adverse P&L impact, and it will be only 25% in H2, driven by the strong uptick. But also remember, strong uptake doesn't happen by itself. You need to reinvest some of those proceeds to make it happen in the following period. And that's what we have done very judiciously. So therefore, driving the strong uptake will bring the breakeven point in -- at a later stage when it's appropriate time. But we're on a very good trajectory here as you see also from a profitability standpoint.</td><td>**Chief Financial Officer:** ë„¤, ìˆ˜ìµì„±ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 2025ë…„ì— ëŒ€í•´ ì–¸ê¸‰í•˜ê³ ì í•˜ëŠ”ë°, ì§€ê¸ˆì´ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ë°œí‘œì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìƒë°˜ê¸° ì‹¤ì  ë°œí‘œ ë•Œ ë„´ë£¨ë¹„ì˜¤ ì¶œì‹œ íˆ¬ìì™€ ê¸°íƒ€ íˆ¬ìë¡œ ì¸í•œ ì†ìµ ì•…í™” ì˜í–¥ì´ ìƒë°˜ê¸°ì— 60%, í•˜ë°˜ê¸°ì— 40%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆë˜ ì ì„ ê¸°ì–µí•˜ì‹¤ ê²ë‹ˆë‹¤. ì—¬ê¸°ì„œ ì—…ë°ì´íŠ¸ë¥¼ ë“œë¦¬ìë©´, ìƒë°˜ê¸°ì— ì†ìµ ì•…í™” ì˜í–¥ì˜ 75%ê°€ ë°œìƒí–ˆê³ , í•˜ë°˜ê¸°ì—ëŠ” 25%ë§Œ ë°œìƒí•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ê°•ë ¥í•œ ë§¤ì¶œ ìƒìŠ¹ì„¸ì— ê¸°ì¸í•©ë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ ê¸°ì–µí•˜ì…”ì•¼ í•  ì ì€, ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥ì´ ì €ì ˆë¡œ ì¼ì–´ë‚˜ëŠ” ê²ƒì€ ì•„ë‹ˆë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¤ìŒ ê¸°ê°„ì— ì´ë¥¼ ì‹¤í˜„í•˜ê¸° ìœ„í•´ì„œëŠ” ìˆ˜ìµì˜ ì¼ë¶€ë¥¼ ì¬íˆ¬ìí•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì´ë¥¼ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ì‹¤í–‰í•´ì™”ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ê²ƒì´ ì†ìµë¶„ê¸°ì  ë„ë‹¬ ì‹œì ì„ ì ì ˆí•œ ì‹œê¸°ë¡œ ê°€ì ¸ê°ˆ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìˆ˜ìµì„± ê´€ì ì—ì„œ ë³´ì‹œë‹¤ì‹œí”¼ ìš°ë¦¬ëŠ” ë§¤ìš° ì¢‹ì€ ê¶¤ë„ì— ì˜¬ë¼ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Shyam Kotadia: Goldman Sachs Group, Inc., Research Division Very, very sorry. It broke up a little bit when you said it will bring the breakeven point as -- can you just repeat that lastly on the breakeven point?</td><td>**Shyam Kotadia:** ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, ì†ìµë¶„ê¸°ì  ê´€ë ¨ ë§ì”€í•˜ì‹¤ ë•Œ ì—°ê²°ì´ ì¡°ê¸ˆ ëŠê²¼ìŠµë‹ˆë‹¤. ì†ìµë¶„ê¸°ì ì— ëŒ€í•´ ë§ˆì§€ë§‰ ë¶€ë¶„ì„ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chief Financial Officer: Yes. It will bring breakeven point in because the strong uptake delivers additional profitability. But we don't want to comment on that right now. We said it back today it's sometime in '27. So let's not get into any details. We will do that at the appropriate point in time.</td><td>**Chief Financial Officer:** ë„¤, ê°•ë ¥í•œ ìˆ˜ìš”ê°€ ì¶”ê°€ì ì¸ ìˆ˜ìµì„±ì„ ê°€ì ¸ì˜¤ê¸° ë•Œë¬¸ì— ì†ìµë¶„ê¸°ì ì— ë„ë‹¬í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ê¸ˆ ì´ ì‹œì ì—ì„œ êµ¬ì²´ì ì¸ ì–¸ê¸‰ì€ í•˜ê³  ì‹¶ì§€ ì•ŠìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ 27ë…„ ì¤‘ ì–´ëŠ ì‹œì ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì„¸ë¶€ ì‚¬í•­ì— ëŒ€í•´ì„œëŠ” ì ì ˆí•œ ì‹œê¸°ì— ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And the next question comes from the line of Benjamin Jackson from Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì œí”„ë¦¬ìŠ¤ì˜ ë²¤ìë¯¼ ì­ìŠ¨ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Benjamin Jackson: Jefferies LLC, Research Division Great. Thank You for the question. One on Relfydess, if I may. I think you've spoken fairly positively about it for a number of quarters now and the ongoing launches. But is there perhaps any more depth in the color that you can provide to us even around the relative size in terms of the entire neuromodulator number that you're putting out? And then thinking about your strategy and how you launch it, is there more color you can provide about the uptake, but also how you balance the commercialization process between Dysport and Relfydess and then how that matters for the U.S. too?</td><td>**Benjamin Jackson:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. Relfydessì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì´ ì œí’ˆê³¼ ì§€ì†ì ì¸ ì¶œì‹œì— ëŒ€í•´ ìƒë‹¹íˆ ê¸ì •ì ìœ¼ë¡œ ë§ì”€ë“œë ¤ ì™”ìŠµë‹ˆë‹¤. ì „ì²´ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) ë§¤ì¶œ ê·œëª¨ ì¸¡ë©´ì—ì„œ ì¢€ ë” êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ë§ì”€ë“œë¦´ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. <br><br>ì¶œì‹œ ì „ëµê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì‹œì¥ ìˆ˜ìš©ë„ì— ëŒ€í•œ ì¶”ê°€ ì •ë³´ë¥¼ ì œê³µí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ Dysportì™€ Relfydess ê°„ì˜ ìƒì—…í™” í”„ë¡œì„¸ìŠ¤ë¥¼ ì–´ë–»ê²Œ ê· í˜•ìˆê²Œ ê°€ì ¸ê°€ê³  ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì´ê²ƒì´ ë¯¸êµ­ ì‹œì¥ì— ì–´ë–¤ ì˜ë¯¸ë¥¼ ê°–ëŠ”ì§€ì— ëŒ€í•´ì„œë„ ë” ìì„¸íˆ ì„¤ëª…ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>í˜„ì¬ RelfydessëŠ” ìˆœì¡°ë¡­ê²Œ ì‹œì¥ì— ì•ˆì°©í•˜ê³  ìˆìœ¼ë©°, ë‘ ì œí’ˆ ê°„ì˜ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµì„ í†µí•´ ê°ê°ì˜ ê°•ì ì„ ì‚´ë¦¬ë©´ì„œ ì „ì²´ ì‹ ê²½ì¡°ì ˆì œ ì‹œì¥ì—ì„œì˜ ì…ì§€ë¥¼ ê°•í™”í•´ ë‚˜ê°€ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì˜ ê²½ìš°, ì´ëŸ¬í•œ ë³µìˆ˜ ì œí’ˆ ì „ëµì´ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ì™€ ê³ ê° ë‹ˆì¦ˆ ì¶©ì¡±ì— ì¤‘ìš”í•œ ì—­í• ì„ í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. I think you have to take the background here. Since 2019, when we as a team took over, we have shown incredible growth of Dysport around the globe. So of course, we continue to support Dysport. It's an incredibly strong product. It competes well against BOTOX. We are launching it even in more and more countries. So for us, that's the most important product we have right now. We are now launching another product and the way we've launched that is we know that in the neuromodulator space, there are still... [Technical Difficulty]</td><td>**CEO & Director:** ë„¤. ì—¬ê¸°ì„œ ë°°ê²½ì„ ë§ì”€ë“œë ¤ì•¼ í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤. 2019ë…„ ì €í¬ íŒ€ì´ ë§¡ì€ ì´í›„ë¡œ, ì „ ì„¸ê³„ì ìœ¼ë¡œ Dysportì˜ ë†€ë¼ìš´ ì„±ì¥ì„ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‹¹ì—°íˆ Dysportì— ëŒ€í•œ ì§€ì›ì„ ê³„ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ê°•ë ¥í•œ ì œí’ˆì´ê³ , BOTOXì™€ì˜ ê²½ìŸì—ì„œë„ ìš°ìœ„ë¥¼ ì í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë” ë§ì€ êµ­ê°€ì—ì„œ ì¶œì‹œë¥¼ ì§„í–‰í•˜ê³  ìˆê¸°ë„ í•©ë‹ˆë‹¤. í˜„ì¬ë¡œì„œëŠ” ì €í¬ê°€ ë³´ìœ í•œ ê°€ì¥ ì¤‘ìš”í•œ ì œí’ˆì…ë‹ˆë‹¤. ì´ì œ ë˜ ë‹¤ë¥¸ ì œí’ˆì„ ì¶œì‹œí•˜ê³  ìˆëŠ”ë°, ì¶œì‹œ ë°©ì‹ì„ ë³´ë©´ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) ì‹œì¥ì— ì—¬ì „íˆ... [ê¸°ìˆ ì  ë¬¸ì œ]</td></tr>
<tr><td>Benjamin Jackson: Jefferies LLC, Research Division I'm not sure I caught any -- like three quarters of that due to the line breaking up. I don't know whether you could repeat it at all. Sorry about that. I'm not sure if it's just me.</td><td>**Benjamin Jackson:** ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, íšŒì„  ìƒíƒœê°€ ì¢‹ì§€ ì•Šì•„ì„œ ë§ì”€í•˜ì‹  ë‚´ìš©ì˜ 4ë¶„ì˜ 3 ì •ë„ë¥¼ ì œëŒ€ë¡œ ë“£ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ê°€ëŠ¥í•˜ì‹œë‹¤ë©´ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹¤ê¹Œìš”? ì œ ìª½ ë¬¸ì œì¸ì§€ëŠ” ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Sorry about that. Yes. So we're really sorry about that. We seem to have some technical issues today. [Technical Difficulty]</td><td>**CEO & Director:** ì£„ì†¡í•©ë‹ˆë‹¤. ë„¤, ì •ë§ ì£„ì†¡í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ê¸°ìˆ ì ì¸ ë¬¸ì œê°€ ì¢€ ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. [ê¸°ìˆ ì  ë¬¸ì œ]</td></tr>
<tr><td>CEO & Director: Okay. Good. Okay. So I apologize. Strong results, not so strong technical execution today. So I apologize for that. But do you want me to repeat the -- sorry, it was a bit long, but I'm happy to repeat it. Is that what you would like me to do?</td><td>**CEO & Director:** ë„¤, ì•Œê² ìŠµë‹ˆë‹¤. ì¢‹ìŠµë‹ˆë‹¤. ì£„ì†¡í•©ë‹ˆë‹¤. ì‹¤ì ì€ ê°•í–ˆì§€ë§Œ ì˜¤ëŠ˜ ê¸°ìˆ ì ì¸ ì§„í–‰ì´ ì›í™œí•˜ì§€ ëª»í–ˆë„¤ìš”. ê·¸ ì  ì‚¬ê³¼ë“œë¦½ë‹ˆë‹¤. ì§ˆë¬¸ì„ ë‹¤ì‹œ ë§ì”€ë“œë¦´ê¹Œìš”? ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ ì§ˆë¬¸ì´ ì¢€ ê¸¸ì—ˆëŠ”ë°, ê¸°êº¼ì´ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ë ‡ê²Œ í•´ë“œë¦´ê¹Œìš”?</td></tr>
<tr><td>Benjamin Jackson: Jefferies LLC, Research Division Please, that'll be really useful if so, thank you.</td><td>**Benjamin Jackson:** ê·¸ë ‡ê²Œ í•´ì£¼ì‹œë©´ ì •ë§ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: I really apologize for these technical issues. So what I was saying is that the way we -- since 2019 have basically been strengthening the commercial execution for Dysport. I think the way we've gained market share. In some cases, we've gained leadership. It's a very strong product. I think you see in most geographies, including the U.S., we continue to gain significant market share also against BOTOX. So when we had the opportunity to launch Relfydess initially in some European countries, the focus was, of course, to maintain the strong momentum of Dysport. We know that there is room for additional optionality among doctors and patients. Relfydess offers certain benefits, of course, fast onset, it's liquid duration. And the doctors that have started using Relfydess, we see that they continue to have a strong preference for that, but we still need to keep in mind that the vast majority of our sales today is Dysport. So what our key strategy is to continue to drive our overall share of the neuromodulator market and given we're now #1 in Europe, #1 in Australia, #1 in Brazil, honing in on the U.S. I think the strategy is working. And remember, our play in injectable aesthetics is a portfolio play. We have multiple opportunities for you to use fillers under the Restylane name, we have Sculptra. And now in many countries, we have 2 options for you if you want to use a neuromodulator. And we think one of the core strength of our gaining market share and holding in on leadership in aesthetics is because we have a broad portfolio approach.</td><td>**CEO & Director:** ì´ëŸ¬í•œ ê¸°ìˆ ì  ë¬¸ì œì— ëŒ€í•´ ì •ë§ ì£„ì†¡í•©ë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦¬ê³ ì í–ˆë˜ ê²ƒì€ 2019ë…„ ì´í›„ ì €í¬ê°€ Dysportì˜ ìƒì—…ì  ì‹¤í–‰ë ¥ì„ ì–´ë–»ê²Œ ê°•í™”í•´ì™”ëŠ”ì§€ì— ëŒ€í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ì €í¬ê°€ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•´ì˜¨ ë°©ì‹ì„ ë³´ì‹œë©´, ì¼ë¶€ ì‹œì¥ì—ì„œëŠ” ë¦¬ë”ì‹­ì„ í™•ë³´í•˜ê¸°ë„ í–ˆìŠµë‹ˆë‹¤. ì •ë§ ê°•ë ¥í•œ ì œí’ˆì´ì£ . ë¯¸êµ­ì„ í¬í•¨í•œ ëŒ€ë¶€ë¶„ì˜ ì§€ì—­ì—ì„œ BOTOX ëŒ€ë¹„í•´ì„œë„ ìƒë‹¹í•œ ì‹œì¥ ì ìœ ìœ¨ì„ ì§€ì†ì ìœ¼ë¡œ í™•ë³´í•˜ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì¼ë¶€ ìœ ëŸ½ êµ­ê°€ì—ì„œ Relfydessë¥¼ ì²˜ìŒ ì¶œì‹œí•  ê¸°íšŒê°€ ìˆì—ˆì„ ë•Œ, ë‹¹ì—°íˆ ì´ˆì ì€ Dysportì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ìœ ì§€í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ì˜ì‚¬ì™€ í™˜ìë“¤ ì‚¬ì´ì—ì„œ ì¶”ê°€ì ì¸ ì„ íƒì§€ì— ëŒ€í•œ ìˆ˜ìš”ê°€ ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. RelfydessëŠ” ë¹ ë¥¸ íš¨ê³¼ ë°œí˜„, ì•¡ìƒ ì œí˜•, ì§€ì† ê¸°ê°„ ë“± íŠ¹ì •í•œ ì¥ì ë“¤ì„ ì œê³µí•©ë‹ˆë‹¤. Relfydessë¥¼ ì‚¬ìš©í•˜ê¸° ì‹œì‘í•œ ì˜ì‚¬ë“¤ì˜ ê²½ìš°, í•´ë‹¹ ì œí’ˆì— ëŒ€í•œ ê°•í•œ ì„ í˜¸ë„ê°€ ì§€ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ ìš°ë¦¬ ë§¤ì¶œì˜ ëŒ€ë¶€ë¶„ì€ ì—¬ì „íˆ Dysportì—ì„œ ë°œìƒí•˜ê³  ìˆë‹¤ëŠ” ì ì„ ì—¼ë‘ì— ë‘ì–´ì•¼ í•©ë‹ˆë‹¤. ìš°ë¦¬ì˜ í•µì‹¬ ì „ëµì€ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) ì‹œì¥ì—ì„œ ì „ì²´ ì ìœ ìœ¨ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ëŠ” ê²ƒì´ë©°, í˜„ì¬ ìœ ëŸ½ 1ìœ„, í˜¸ì£¼ 1ìœ„, ë¸Œë¼ì§ˆ 1ìœ„ë¥¼ ë‹¬ì„±í•œ ìƒí™©ì—ì„œ ë¯¸êµ­ ì‹œì¥ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì „ëµì´ íš¨ê³¼ë¥¼ ë°œíœ˜í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ì£¼ì‚¬ìš© ë¯¸ìš© ì‹œì¥ì—ì„œ ìš°ë¦¬ì˜ ì ‘ê·¼ ë°©ì‹ì€ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµì´ë¼ëŠ” ì ì„ ê¸°ì–µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. Restylane ë¸Œëœë“œë¡œ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ í•„ëŸ¬ ì œí’ˆë“¤ì´ ìˆê³ , Sculptraë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ë§ì€ êµ­ê°€ì—ì„œ ì‹ ê²½ì¡°ì ˆì œë¥¼ ì›í•˜ì‹œëŠ” ê²½ìš° ë‘ ê°€ì§€ ì˜µì…˜ì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. <budget:token_budget>200000</budget:token_budget><br><br>ê·¸ë¦¬ê³  ì €í¬ê°€ ë¯¸ìš© ì‹œì¥ì—ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ì„ ë„ì  ì§€ìœ„ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆëŠ” í•µì‹¬ ê°•ì  ì¤‘ í•˜ë‚˜ëŠ” í­ë„“ì€ í¬íŠ¸í´ë¦¬ì˜¤ ì ‘ê·¼ ë°©ì‹ì„ ê°–ì¶”ê³  ìˆê¸° ë•Œë¬¸ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And then the question comes from line of Yihan Li from Barclays.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ë°”í´ë ˆì´ìŠ¤ì˜ Yihan Li ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ì§ˆë¬¸ì´ ë“¤ì–´ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Yihan Li: Barclays Bank PLC, Research Division Yihan Li from Barclays. Congrats on the on the quarter. I guess I have a question on Nemluvio treatment dynamics. So I acknowledge nemo's launch is still at a very early stage. But I'm still wondering what is the average treatment duration so far in PN and also AD indication separately? So based on our research, it seems like the switch out rate for from Nemluvio remains at a very low level, but slightly increased a little bit in the third quarter versus second quarter. So just curious, any observations on discontinuation rate or like patient experiences so far?</td><td>**Yihan Li:** ë°”í´ë ˆì´ì¦ˆì˜ ì´í•œ ë¦¬ì…ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤(Nemluvio)ì˜ ì¹˜ë£Œ ì—­í•™(treatment dynamics)ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë„´ë£¨ë¹„ì˜¤ì˜ ì¶œì‹œê°€ ì•„ì§ ì´ˆê¸° ë‹¨ê³„ë¼ëŠ” ì ì€ ì•Œê³  ìˆìŠµë‹ˆë‹¤ë§Œ, í˜„ì¬ê¹Œì§€ ê²°ì ˆì„± ê°€ë ¤ì›€ì¦(PN)ê³¼ ì•„í† í”¼ í”¼ë¶€ì—¼(AD) ì ì‘ì¦ì—ì„œ ê°ê° í‰ê·  ì¹˜ë£Œ ê¸°ê°„ì´ ì–´ëŠ ì •ë„ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì €í¬ ì¡°ì‚¬ì— ë”°ë¥´ë©´ ë„´ë£¨ë¹„ì˜¤ì—ì„œ ë‹¤ë¥¸ ì¹˜ë£Œì œë¡œ ì „í™˜í•˜ëŠ” ë¹„ìœ¨ì´ ë§¤ìš° ë‚®ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, 3ë¶„ê¸°ì— 2ë¶„ê¸° ëŒ€ë¹„ ì†Œí­ ì¦ê°€í•œ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ê¹Œì§€ ì¤‘ë‹¨ìœ¨ì´ë‚˜ í™˜ì ê²½í—˜ê³¼ ê´€ë ¨í•´ì„œ ê´€ì°°í•˜ì‹  ë‚´ìš©ì´ ìˆìœ¼ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. There's one advantage of being the CEO and a physician is I interact with a lot of physicians. I just spent time yesterday with 2 of them. So they both have a very large number of patients on the product and I go together with my colleagues on many field visits. So what you're observing is also what we hear back from the physicians, and we're seeing in the market research, the dropout rate has been really low. We still see that every 4 week is the preferred duration, but we are now seeing the doctors and stable patients that have been itch-free slept well at night, that they're now thinking about going or have already started to go to every 8 weeks, which they see as a huge advantage. So what we're seeing is that the initial feedback from patients and physicians has been reconfirming the fast itch-release. It's reconfirmed the very positive impact on sleep and quality of life. It also has been surprising for many physicians that they feel that the skin clearance is above what their expectations. They had strong expectations in PN, but maybe not so in AD, and they are in the patients they select to be on the product. So the fact that we also can be used first line, the fact that we have a very large portion of our patients being biological naive. It all probably speaks to the fact that for the moment, along with incredibly strong access, 80-plus percent in commercial plans, we see low dropout rates. Of course, like any IL-13 and IL-31, it's not going to be for everyone. The physicians have choices to make but the good news is a lot of physicians are starting to use Nemluvio as first-line given its safety profile, given what the fast itch relief but it's way too early to comment on that. And we just basically started to launch in certain parts of the world. We're building out the field force. We've just launched DTC. So it's way too early at this stage to make big bold projections on the brand.</td><td>**CEO & Director:** ë„¤, CEOì´ì ì˜ì‚¬ë¡œì„œ ëˆ„ë¦¬ëŠ” ì¥ì  ì¤‘ í•˜ë‚˜ëŠ” ë§ì€ ì˜ì‚¬ë“¤ê³¼ êµë¥˜í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì–´ì œë„ ë‘ ë¶„ì˜ ì˜ì‚¬ì™€ ì‹œê°„ì„ ë³´ëƒˆëŠ”ë°, ë‘ ë¶„ ëª¨ë‘ ì´ ì œí’ˆì„ ì²˜ë°©ë°›ëŠ” í™˜ìê°€ ìƒë‹¹íˆ ë§ìŠµë‹ˆë‹¤. ì €ëŠ” ë™ë£Œë“¤ê³¼ í•¨ê»˜ í˜„ì¥ ë°©ë¬¸ì„ ìì£¼ ë‹¤ë‹ˆê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ë‚´ìš©ì€ ì‹¤ì œë¡œ ì˜ì‚¬ë“¤ë¡œë¶€í„° ë“£ê³  ìˆëŠ” í”¼ë“œë°±ê³¼ ì¼ì¹˜í•˜ë©°, ì‹œì¥ ì¡°ì‚¬ì—ì„œë„ í™•ì¸ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘ë‹¨ìœ¨ì€ ì •ë§ ë‚®ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ 4ì£¼ ê°„ê²©ì´ ì„ í˜¸ë˜ëŠ” íˆ¬ì—¬ ì£¼ê¸°ì´ê¸´ í•˜ì§€ë§Œ, ì´ì œëŠ” ê°€ë ¤ì›€ì¦ì´ ì—†ì–´ì§€ê³  ë°¤ì— ìˆ™ë©´ì„ ì·¨í•˜ëŠ” ì•ˆì •ì ì¸ í™˜ìë“¤ì˜ ê²½ìš°, ì˜ì‚¬ë“¤ì´ 8ì£¼ ê°„ê²©ìœ¼ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì„ ê³ ë ¤í•˜ê±°ë‚˜ ì´ë¯¸ ì‹œì‘í•œ ì‚¬ë¡€ë“¤ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ë“¤ì€ ì´ë¥¼ í° ì¥ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ í™˜ìì™€ ì˜ì‚¬ë“¤ë¡œë¶€í„° ë°›ì€ ì´ˆê¸° í”¼ë“œë°±ì´ ë¹ ë¥¸ ê°€ë ¤ì›€ì¦ ì™„í™” íš¨ê³¼ë¥¼ ì¬í™•ì¸ì‹œì¼œ ì£¼ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ìˆ˜ë©´ê³¼ ì‚¶ì˜ ì§ˆì— ëŒ€í•œ ë§¤ìš° ê¸ì •ì ì¸ ì˜í–¥ë„ ì¬í™•ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ë§ì€ ì˜ì‚¬ë“¤ì—ê²Œ ë†€ë¼ìš´ ì ì€ í”¼ë¶€ ê°œì„  íš¨ê³¼ê°€ ê·¸ë“¤ì˜ ì˜ˆìƒì„ ë›°ì–´ë„˜ëŠ”ë‹¤ê³  ëŠë¼ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê²°ì ˆì„± ì–‘ì§„(PN)ì—ì„œëŠ” ë†’ì€ ê¸°ëŒ€ë¥¼ ê°€ì§€ê³  ìˆì—ˆì§€ë§Œ, ì•„í† í”¼ í”¼ë¶€ì—¼(AD)ì—ì„œëŠ” ê·¸ë ‡ì§€ ì•Šì•˜ì„ ìˆ˜ ìˆëŠ”ë°, ì‹¤ì œë¡œ ì œí’ˆì„ ì‚¬ìš©í•˜ë„ë¡ ì„ íƒí•œ í™˜ìë“¤ì—ê²Œì„œ ê·¸ëŸ° ê²°ê³¼ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ìš°ë¦¬ ì œí’ˆì´ 1ì°¨ ì¹˜ë£Œì œë¡œ ì‚¬ìš©ë  ìˆ˜ ìˆë‹¤ëŠ” ì , ê·¸ë¦¬ê³  ìš°ë¦¬ í™˜ìì˜ ìƒë‹¹ ë¶€ë¶„ì´ ìƒë¬¼í•™ì  ì œì œ ë¯¸ê²½í—˜ìë¼ëŠ” ì‚¬ì‹¤, ì´ ëª¨ë“  ê²ƒì´ í˜„ì¬ ìƒí™©ì„ ì„¤ëª…í•´ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì— ìƒì—… ë³´í—˜ì˜ 80% ì´ìƒì´ë¼ëŠ” ë§¤ìš° ê°•ë ¥í•œ ë³´í—˜ ì ìš©ê³¼ í•¨ê»˜, ìš°ë¦¬ëŠ” ë‚®ì€ ì¤‘ë‹¨ìœ¨ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ë‹¤ë¥¸ IL-13, IL-31 ì œì œë“¤ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ ëª¨ë“  í™˜ìì—ê²Œ ì í•©í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ì˜ì‚¬ë“¤ì´ ì„ íƒì„ í•´ì•¼ í•˜ëŠ” ìƒí™©ì´ì§€ë§Œ, ê¸ì •ì ì¸ ì†Œì‹ì€ ë§ì€ ì˜ì‚¬ë“¤ì´ Nemluvioì˜ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ê³¼ ë¹ ë¥¸ ê°€ë ¤ì›€ì¦ ì™„í™” íš¨ê³¼ë¥¼ ê³ ë ¤í•˜ì—¬ 1ì°¨ ì¹˜ë£Œì œë¡œ ì‚¬ìš©í•˜ê¸° ì‹œì‘í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì— ëŒ€í•´ ì–¸ê¸‰í•˜ê¸°ì—ëŠ” ì•„ì§ ë„ˆë¬´ ì´ë¦…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ì œ ë§‰ ì „ ì„¸ê³„ íŠ¹ì • ì§€ì—­ì—ì„œ ì¶œì‹œë¥¼ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. í˜„ì¥ ì˜ì—… ì¡°ì§ì„ êµ¬ì¶•í•˜ê³  ìˆê³ , DTC(ì†Œë¹„ì ì§ì ‘ ê´‘ê³ )ë„ ì´ì œ ë§‰ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ ë‹¨ê³„ì—ì„œ ì´ ë¸Œëœë“œì— ëŒ€í•´ í° ì „ë§ì„ ë‚´ë†“ê¸°ì—ëŠ” ë„ˆë¬´ ì´ë¥¸ ì‹œì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: The other part that helps a lot is the tolerability. Flemming mentioned the lack of side effects, so to speak. But the other part is just that it doesn't seem to sting as much because it's against the main competitor from a large French company. The volume is much, much lower. It's about a quarter. So therefore, the convenience of having to auto inject yourself. And that's also practice that physicians tell us that help people wanting to stay on the ground because it's just convenient. It's highly tolerable. It doesn't hurt as much. So that's some of the learnings we're getting there. Just complementing Flemming's comments.</td><td>**Chief Financial Officer:** ë˜ ë‹¤ë¥¸ ì¤‘ìš”í•œ ë¶€ë¶„ì€ ë‚´ì•½ì„±ì…ë‹ˆë‹¤. í”Œë ˆë°ì´ ë¶€ì‘ìš©ì´ ê±°ì˜ ì—†ë‹¤ëŠ” ì ì„ ì–¸ê¸‰í–ˆëŠ”ë°ìš”. ì¶”ê°€ë¡œ ë§ì”€ë“œë¦¬ë©´, ëŒ€í˜• í”„ë‘ìŠ¤ ê¸°ì—…ì˜ ì£¼ìš” ê²½ìŸ ì œí’ˆê³¼ ë¹„êµí–ˆì„ ë•Œ ì£¼ì‚¬ ì‹œ í†µì¦ì´ í›¨ì”¬ ëœí•œ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. íˆ¬ì—¬ ìš©ëŸ‰ì´ í›¨ì”¬ ì ê±°ë“ ìš”. ì•½ 4ë¶„ì˜ 1 ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìê°€ ì£¼ì‚¬ì˜ í¸ì˜ì„± ì¸¡ë©´ì—ì„œë„ ìš°ìˆ˜í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ì˜ì‚¬ë“¤ë„ í™˜ìë“¤ì´ ì¹˜ë£Œë¥¼ ì§€ì†í•˜ê³ ì í•˜ëŠ” ì´ìœ ê°€ ë°”ë¡œ ì´ëŸ° í¸ì˜ì„± ë•Œë¬¸ì´ë¼ê³  ë§í•©ë‹ˆë‹¤. ë‚´ì•½ì„±ì´ ë›°ì–´ë‚˜ê³  í†µì¦ë„ ì ìœ¼ë‹ˆê¹Œìš”. ì´ê²ƒì´ ì €í¬ê°€ í˜„ì¥ì—ì„œ ì–»ê³  ìˆëŠ” ì¸ì‚¬ì´íŠ¸ì…ë‹ˆë‹¤. í”Œë ˆë°ì˜ ì˜ê²¬ì— ë³´ì¶© ì„¤ëª…ì„ ë“œë ¸ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: But the most important is to realize, we're on a journey. We're basically well into the larger PN. We're basically now starting significantly the launch of AD. When you speak to physicians and what we see in market research, that the ones that started to use Nemluvio, particularly in PN initially, they had a lineup of patients that had been difficult to treat for them with other products that didn't want the JAK. So we probably got a pretty severe group of patients initially. Now we're moving into, I think, a broader group of patients and also first line in many cases. So we'll see where that takes us.</td><td>**CEO & Director:** í•˜ì§€ë§Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ìš°ë¦¬ê°€ ì—¬ì • ì¤‘ì— ìˆë‹¤ëŠ” ì ì„ ì¸ì‹í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¯¸ ëŒ€ê·œëª¨ PN(ê²°ì ˆì„± ì–‘ì§„) ì‹œì¥ì— ìƒë‹¹íˆ ì§„ì…í•´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ë³¸ê²©ì ìœ¼ë¡œ AD(ì•„í† í”¼ í”¼ë¶€ì—¼) ì¶œì‹œë¥¼ ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ë“¤ê³¼ ëŒ€í™”í•˜ê³  ì‹œì¥ ì¡°ì‚¬ë¥¼ ë³´ë©´, íŠ¹íˆ ì´ˆê¸°ì— PNì—ì„œ Nemluvioë¥¼ ì‚¬ìš©í•˜ê¸° ì‹œì‘í•œ ì˜ì‚¬ë“¤ì€ ë‹¤ë¥¸ ì œí’ˆìœ¼ë¡œ ì¹˜ë£Œí•˜ê¸° ì–´ë ¤ì› ê³  JAK ì–µì œì œë¥¼ ì›í•˜ì§€ ì•Šì•˜ë˜ í™˜ìë“¤ì„ ëŒ€ê¸°ì‹œì¼œ ë†“ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ˆê¸°ì—ëŠ” ì•„ë§ˆë„ ê½¤ ì¤‘ì¦ í™˜ìêµ°ì„ í™•ë³´í–ˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ëŠ” ë” ê´‘ë²”ìœ„í•œ í™˜ìêµ°ìœ¼ë¡œ ì´ë™í•˜ê³  ìˆê³ , ë§ì€ ê²½ìš° 1ì°¨ ì¹˜ë£Œì œë¡œë„ ì‚¬ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ ìš°ë¦¬ë¥¼ ì–´ë””ë¡œ ì´ëŒì§€ ì§€ì¼œë³¼ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And the next question comes from the line of Victor Floch from BNP Paribas Exane.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BNP íŒŒë¦¬ë°” ì—‘ì„¸ì¸ì˜ ë¹…í„° í”Œë¡œí ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Victor Floch: BNP Paribas Exane, Research Division My question is on Relfydess, and I was wondering if you could comment on the timeline for securing the U.S. capacity and whether bringing this capacity online might shift your neuromodulator's product mix further towards Relfydess, considering that the rest of your toxin portfolio is still expected to be manufactured out of the U.K.</td><td>**Victor Floch:** ì§ˆë¬¸ ì£¼ì‹  Relfydessì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‚´ ìƒì‚° ëŠ¥ë ¥ í™•ë³´ ì¼ì •ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì´ ìƒì‚° ëŠ¥ë ¥ì´ ê°€ë™ë˜ë©´ ì‹ ê²½ì¡°ì ˆì œ ì œí’ˆ ë¯¹ìŠ¤ê°€ Relfydess ìª½ìœ¼ë¡œ ë” ì´ë™í•  ê°€ëŠ¥ì„±ì´ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ë‚˜ë¨¸ì§€ í†¡ì‹  í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì—¬ì „íˆ ì˜êµ­ì—ì„œ ìƒì‚°ë  ì˜ˆì •ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë¯¸êµ­ ìƒì‚° ëŠ¥ë ¥ í™•ë³´ëŠ” ìš°ë¦¬ì—ê²Œ ì¤‘ìš”í•œ ì „ëµì  ì´ì ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ íƒ€ì„ë¼ì¸ì„ ì§„í–‰ ì¤‘ì´ë©°, ì´ëŠ” ê³µê¸‰ë§ ì•ˆì •ì„±ê³¼ ì‹œì¥ ëŒ€ì‘ë ¥ ì¸¡ë©´ì—ì„œ ìƒë‹¹í•œ ê°œì„ ì„ ê°€ì ¸ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. <br><br>ì œí’ˆ ë¯¹ìŠ¤ ì¸¡ë©´ì—ì„œ ë³´ë©´, ë¯¸êµ­ ìƒì‚°ì´ ì‹œì‘ë˜ë©´ Relfydessì˜ ë¹„ì¤‘ì´ ìì—°ìŠ¤ëŸ½ê²Œ ì¦ê°€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì „ì²´ í†¡ì‹  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê· í˜•ì„ ìœ ì§€í•˜ë©´ì„œ ê° ì œí’ˆì˜ ì‹œì¥ í¬ì§€ì…”ë‹ê³¼ ê³ ê° ë‹ˆì¦ˆì— ë§ì¶° ìµœì í™”í•´ ë‚˜ê°ˆ ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: No. Our focus is still and Ipsen is doing an excellent job is to continue to manufacture in a reliable manner. In the history, we had some stock outs, but we've had a very good record now of delivery on time, and that's very important because of the very strong growth rate that we're seeing with Relfydess. We had a bit of subdued launch in Europe because we are new to the manufacturing of neuromodulators. We built a totally new manufacturing site in Sweden. So we were a little bit cautious that we would not run out of stock, and we have not done that. We prioritized which countries we were launching in. The other thing that was very important and is still impacting a little bit of our launch trajectory for Relfydess is we have to run a lot of batches to prepare for the filing of the complete response letter in -- with the FDA. So we have choices to be made all the time between making sure we have supply for the products where we are -- in the countries where we're also launched and making sure we have batches enough for answering all the questions that we have to answer with the FDA. As I see right now because, remember, it's a lot of batches that have to be run and we have to do testing on these batches. Everything seems to be going in the right direction, whether it's going to be in December or flip into January, I do not know, but I think we're on track.</td><td>**CEO & Director:** ì•„ë‹™ë‹ˆë‹¤. ì €í¬ì˜ ì´ˆì ì€ ì—¬ì „íˆ Ipsenì´ í›Œë¥­í•˜ê²Œ ìˆ˜í–‰í•˜ê³  ìˆëŠ” ê²ƒì²˜ëŸ¼ ì•ˆì •ì ì¸ ë°©ì‹ìœ¼ë¡œ ì œì¡°ë¥¼ ì§€ì†í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê³¼ê±°ì— ì¬ê³  ë¶€ì¡± ì‚¬íƒœê°€ ëª‡ ì°¨ë¡€ ìˆì—ˆì§€ë§Œ, í˜„ì¬ëŠ” ì •ì‹œ ë‚©í’ˆì— ìˆì–´ ë§¤ìš° ìš°ìˆ˜í•œ ê¸°ë¡ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” Relfydessì˜ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ë¥ ì„ ê³ ë ¤í•  ë•Œ ëŒ€ë‹¨íˆ ì¤‘ìš”í•©ë‹ˆë‹¤. ìœ ëŸ½ì—ì„œëŠ” ë‹¤ì†Œ ì¡°ì‹¬ìŠ¤ëŸ¬ìš´ ì¶œì‹œë¥¼ ì§„í–‰í–ˆëŠ”ë°, ì´ëŠ” ì €í¬ê°€ ì‹ ê²½ì¡°ì ˆì œ(neuromodulator) ì œì¡°ì— ìƒˆë¡­ê²Œ ì§„ì…í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìŠ¤ì›¨ë´ì— ì™„ì „íˆ ìƒˆë¡œìš´ ì œì¡° ì‹œì„¤ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì¬ê³  ë¶€ì¡± ì‚¬íƒœê°€ ë°œìƒí•˜ì§€ ì•Šë„ë¡ ë‹¤ì†Œ ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í–ˆê³ , ì‹¤ì œë¡œ ê·¸ëŸ° ì¼ì€ ë°œìƒí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì–´ëŠ êµ­ê°€ì—ì„œ ë¨¼ì € ì¶œì‹œí• ì§€ ìš°ì„ ìˆœìœ„ë¥¼ ì •í•´ì„œ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì¤‘ìš”í•œ ì ì€, ê·¸ë¦¬ê³  í˜„ì¬ë„ Relfydessì˜ ì¶œì‹œ ê¶¤ë„ì— ì•½ê°„ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆëŠ” ë¶€ë¶„ì¸ë°ìš”, FDAì— ì œì¶œí•  ì™„ì „ ë‹µë³€ì„œ(complete response letter) ì¤€ë¹„ë¥¼ ìœ„í•´ ìƒë‹¹íˆ ë§ì€ ë°°ì¹˜ë¥¼ ìƒì‚°í•´ì•¼ í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” í•­ìƒ ì„ íƒì˜ ê¸°ë¡œì— ì„œê²Œ ë©ë‹ˆë‹¤. ì´ë¯¸ ì¶œì‹œí•œ êµ­ê°€ë“¤ì—ì„œ ì œí’ˆ ê³µê¸‰ì„ í™•ë³´í•˜ëŠ” ê²ƒê³¼, FDAì— ë‹µë³€í•´ì•¼ í•  ëª¨ë“  ì§ˆë¬¸ë“¤ì„ ìœ„í•œ ì¶©ë¶„í•œ ë°°ì¹˜ë¥¼ í™•ë³´í•˜ëŠ” ê²ƒ ì‚¬ì´ì—ì„œ ë§ì´ì£ .<br><br>í˜„ì¬ ì œê°€ ë³´ê¸°ì—ëŠ”, ê¸°ì–µí•˜ì…”ì•¼ í•  ì ì€ ìƒì‚°í•´ì•¼ í•  ë°°ì¹˜ê°€ ì •ë§ ë§ê³  ì´ ë°°ì¹˜ë“¤ì— ëŒ€í•œ í…ŒìŠ¤íŠ¸ë„ ì§„í–‰í•´ì•¼ í•œë‹¤ëŠ” ê²ƒì¸ë°ìš”, ëª¨ë“  ê²ƒì´ ì˜¬ë°”ë¥¸ ë°©í–¥ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. 12ì›”ì´ ë ì§€ 1ì›”ë¡œ ë„˜ì–´ê°ˆì§€ëŠ” í™•ì‹¤í•˜ì§€ ì•Šì§€ë§Œ, ê³„íšëŒ€ë¡œ ì§„í–‰ë˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: [Operator Instructions] And it comes the line of Richard Vosser from JPMorgan.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] JPMorganì˜ Richard Vosser ë‹˜ ì°¨ë¡€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Richard Vosser: JPMorgan Chase & Co, Research Division Question on Relfydess and the approval in the UAE. Obviously, as you said, Flemming, no presence there. So I'm just thinking how would you size the opportunity? And how you would attack that opportunity in other areas where you don't have Dysport under your control? And how we should think about the opportunity in those areas for Relfydess?</td><td>**Richard Vosser:** Relfydessì™€ UAE ìŠ¹ì¸ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ê·¸ ì§€ì—­ì—ëŠ” í˜„ì¬ ì…ì§€ê°€ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ Dysportë¥¼ ì§ì ‘ ê´€ë¦¬í•˜ì§€ ì•ŠëŠ” ë‹¤ë¥¸ ì§€ì—­ì—ì„œ ì´ ê¸°íšŒë¥¼ ì–´ë–»ê²Œ í‰ê°€í•˜ê³  ê³„ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ê·¸ëŸ¬í•œ ì§€ì—­ì—ì„œ Relfydess ê¸°íšŒë¥¼ ì–´ë–»ê²Œ ê³µëµí•  ê³„íšì´ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. í•´ë‹¹ ì§€ì—­ë“¤ì—ì„œì˜ ê¸°íšŒë¥¼ ì–´ë–»ê²Œ ë°”ë¼ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Well, the Middle East is a region that is near and dear in my heart as it is in the drug department. Because as we go through a lot of challenges in that region, we had just [Technical Difficulty] so we set out of a venture, which was not a easy venture through arbitration and a whole, in my case, a kind of lawsuit to fight and secure our ability to sell our products in the region. So first, we make really good progress with fillers, now with Sculptra, now comes the next stage, which is with Relfydess, we will be -- because Relfydess is approved in March at the beginning of the year. It's a region that continues to surprise me. I recently was at a conference, AMWC in Dubai. I heard that there will be 3,000 people at the conference. I think there were 6,000 people there. And I saw the interest in Relfydess, which we just got approved in time. So I cannot quantify at this stage, but it's also coincides with the fact that this is one of the regions where there's also very significant treatment for GLP-1. It's almost OTC. So I think both what we're seeing for Sculptra and for fillers is very strong growth. And I imagine now having the full [Technical Difficulty] with Relfydess, should help us to secure more market share overall in injectable aesthetics. And as you know, a lot of people from different parts of Europe are gravitating towards now also putting their clinics in UAE. And the bigger market is, of course, at KSA or Saudi, so [Technical Difficulty] so I'm optimistic about it, but it's going to take a bit of time.</td><td>**CEO & Director:** ì¤‘ë™ ì§€ì—­ì€ ì €ì™€ ì•½í’ˆ ë¶€ì„œ ëª¨ë‘ì—ê²Œ ë§¤ìš° íŠ¹ë³„í•œ ì˜ë¯¸ê°€ ìˆëŠ” ì‹œì¥ì…ë‹ˆë‹¤. ê·¸ ì§€ì—­ì—ì„œ ë§ì€ ì–´ë ¤ì›€ì„ ê²ªì—ˆëŠ”ë°, [ê¸°ìˆ ì  ë¬¸ì œ] ë²¤ì²˜ ì‚¬ì—…ì„ ì •ë¦¬í–ˆê³ , ì¤‘ì¬ì™€ ì†Œì†¡ ê³¼ì •ì„ ê±°ì³ í•´ë‹¹ ì§€ì—­ì—ì„œ ì œí’ˆì„ íŒë§¤í•  ìˆ˜ ìˆëŠ” ê¶Œë¦¬ë¥¼ í™•ë³´í•˜ê¸° ìœ„í•´ ì‹¸ì›Œì•¼ í–ˆìŠµë‹ˆë‹¤. ì‰½ì§€ ì•Šì€ ê³¼ì •ì´ì—ˆì£ . ê·¸ë˜ì„œ ë¨¼ì € í•„ëŸ¬ ì œí’ˆìœ¼ë¡œ ì •ë§ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë’€ê³ , ì´ì œëŠ” ìŠ¤ì»¬íŠ¸ë¼(Sculptra)ë¡œë„ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìœ¼ë©°, ë‹¤ìŒ ë‹¨ê³„ë¡œëŠ” ë¦´íŒŒì´ë°ìŠ¤(Relfydess)ê°€ ì˜¬í•´ ì´ˆ 3ì›”ì— ìŠ¹ì¸ì„ ë°›ì•˜ê¸° ë•Œë¬¸ì— ì´ ì œí’ˆìœ¼ë¡œ ì§„ì¶œí•  ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ì´ ì§€ì—­ì€ ê³„ì†í•´ì„œ ì €ë¥¼ ë†€ë¼ê²Œ í•©ë‹ˆë‹¤. ìµœê·¼ ë‘ë°”ì´ì—ì„œ ì—´ë¦° AMWC ì»¨í¼ëŸ°ìŠ¤ì— ì°¸ì„í–ˆëŠ”ë°, 3ì²œ ëª… ì •ë„ê°€ ì°¸ì„í•  ê²ƒìœ¼ë¡œ ë“¤ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì‹¤ì œë¡œëŠ” 6ì²œ ëª…ì´ ì°¸ì„í–ˆë”êµ°ìš”. Relfydessì— ëŒ€í•œ ê´€ì‹¬ë„ í™•ì¸í–ˆëŠ”ë°, ì œë•Œ ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. í˜„ ë‹¨ê³„ì—ì„œ ìˆ˜ì¹˜í™”í•  ìˆ˜ëŠ” ì—†ì§€ë§Œ, ì´ ì§€ì—­ì´ GLP-1 ì¹˜ë£Œê°€ ë§¤ìš° í™œë°œí•œ ê³³ì´ë¼ëŠ” ì ê³¼ë„ ì¼ì¹˜í•©ë‹ˆë‹¤. ê±°ì˜ ì¼ë°˜ì˜ì•½í’ˆ(OTC) ìˆ˜ì¤€ì´ì£ . Sculptraì™€ í•„ëŸ¬ ëª¨ë‘ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ì œ Relfydessê¹Œì§€ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°–ì¶”ê²Œ ë˜ë©´ì„œ ì£¼ì‚¬í˜• ë¯¸ìš© ì‹œì¥ ì „ë°˜ì—ì„œ ë” ë§ì€ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•˜ëŠ” ë° ë„ì›€ì´ ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ìœ ëŸ½ ê°ì§€ì˜ ë§ì€ ì‚¬ëŒë“¤ì´ ì´ì œ UAEì— í´ë¦¬ë‹‰ì„ ê°œì„¤í•˜ëŠ” ìª½ìœ¼ë¡œ ì›€ì§ì´ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ë” í° ì‹œì¥ì€ KSA, ì¦‰ ì‚¬ìš°ë””ì•„ë¼ë¹„ì•„ì´ê¸° ë•Œë¬¸ì— ë‚™ê´€ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë‹¤ì†Œ ì‹œê°„ì€ ê±¸ë¦´ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: But let me just add from a profitability standpoint, Relfydess in the Middle East is super attractive because from the first unit onwards, it's royalty free. We don't have to pay any royalties to Ipsen. So that's also very attractive profitability-wise. And it is, of course, an added brand and over time will be a contributor to our profitability and margin expansion.</td><td>**Chief Financial Officer:** ìˆ˜ìµì„± ê´€ì ì—ì„œ í•œ ê°€ì§€ ë” ë§ì”€ë“œë¦¬ìë©´, ì¤‘ë™ ì§€ì—­ì˜ RelfydessëŠ” ë§¤ìš° ë§¤ë ¥ì ì…ë‹ˆë‹¤. ì²« íŒë§¤ ë‹¨ìœ„ë¶€í„° ë¡œì—´í‹°ê°€ ë©´ì œë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. Ipsenì— ì–´ë– í•œ ë¡œì—´í‹°ë„ ì§€ë¶ˆí•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìˆ˜ìµì„± ì¸¡ë©´ì—ì„œë„ ë§¤ìš° ë§¤ë ¥ì ì…ë‹ˆë‹¤. ë¬¼ë¡  ì´ëŠ” ì¶”ê°€ì ì¸ ë¸Œëœë“œì´ë©°, ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ìš°ë¦¬ì˜ ìˆ˜ìµì„±ê³¼ ë§ˆì§„ í™•ëŒ€ì— ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And now we're going to take our last question for today. And it comes from the line of Natalia Webster from RBC.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ì´ì œ ì˜¤ëŠ˜ ë§ˆì§€ë§‰ ì§ˆë¬¸ì„ ë°›ê² ìŠµë‹ˆë‹¤. RBCì˜ ë‚˜íƒˆë¦¬ì•„ ì›¹ìŠ¤í„°ë‹˜ê»˜ì„œ ì§ˆë¬¸í•˜ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Natalia Webster: RBC Capital Markets, Research Division It's just a follow-up on what you mentioned around Relfydess in contribution to margins. Are you able to comment a bit more on when you expect this to be a meaningful driver to margins? Do we still need to see the U.S. approval? And then those royalty caps to be reached in major markets for this?</td><td>**Natalia Webster:** RBC ìºí”¼íƒˆ ë§ˆì¼“ì˜ ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ ë‚´ìš©ë§Œ ë²ˆì—­í•˜ì‹œë©´ ë©ë‹ˆë‹¤. <br><br>ì§ˆë¬¸ ë‚´ìš©ì„ ë³´ë©´, Relfydessì˜ ë§ˆì§„ ê¸°ì—¬ë„ì™€ ê´€ë ¨í•˜ì—¬ ì–¸ì œì¯¤ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„  ìš”ì¸ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ì§€, ê·¸ë¦¬ê³  ì´ë¥¼ ìœ„í•´ ë¯¸êµ­ ìŠ¹ì¸ê³¼ ì£¼ìš” ì‹œì¥ì—ì„œì˜ ë¡œì—´í‹° ìƒí•œì„  ë„ë‹¬ì´ ì—¬ì „íˆ í•„ìš”í•œì§€ ë¬»ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‹µë³€ ë‚´ìš©ì„ ì œê³µí•´ì£¼ì‹œë©´ ìì—°ìŠ¤ëŸ¬ìš´ í•œêµ­ì–´ë¡œ ë²ˆì—­í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Yes. Thank you, Natalia. Yes, you're right. I mean, from an overall margin standpoint, think about what Flemming just said earlier. These ramps go slowly, steadily, but this is really sticky stuff. But it ramps slowly and remember, you'll never have a patent cliff either. So we really want to do it the right way that doctors like it, patients like it [Technical Difficulty] patient doctor discussions. So that's what it is. And then from a margin standpoint, I just said, look, there are some geographies like UAE and Middle East that are royalty free because we did not have the right to Dysport there. So that's really attractive. So there, you have a contribution right from the get-go. And then other territories in which we have the right to Dysport, that's in various geographies. And there, you have to hit certain levels. Really in the U.S., once approved, we would get -- given the size of the growth of the market, we would get to that threshold quicker than in the other territories where we have to pay royalties. So there takes a little bit longer. But overall, a very good trajectory and the excitement from patients seeing that fast onset and health care professionals fast onset and the long duration, that's really what we should focus on. And profitability will follow and it's very attractive for us. So that will almost take care of itself.</td><td>**Chief Financial Officer:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Natalia. ë§ìŠµë‹ˆë‹¤. ì „ì²´ì ì¸ ë§ˆì§„ ê´€ì ì—ì„œ ë³´ë©´, ì•„ê¹Œ Flemmingì´ ë§ì”€ë“œë¦° ë‚´ìš©ì„ ìƒê°í•´ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì´ëŸ¬í•œ í™•ëŒ€ëŠ” ì²œì²œíˆ, ê¾¸ì¤€íˆ ì§„í–‰ë˜ì§€ë§Œ ì •ë§ ì§€ì†ì„±ì´ ê°•í•œ ì‚¬ì—…ì…ë‹ˆë‹¤. ë‹¤ë§Œ ì²œì²œíˆ í™•ëŒ€ë˜ê³ , íŠ¹í—ˆ ë§Œë£Œ ìœ„í—˜ë„ ì „í˜€ ì—†ë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ì…”ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì˜ì‚¬ë“¤ì´ ì¢‹ì•„í•˜ê³ , í™˜ìë“¤ì´ ì¢‹ì•„í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì œëŒ€ë¡œ ì§„í–‰í•˜ê³ ì í•©ë‹ˆë‹¤. ì˜ì‚¬-í™˜ì ê°„ ë…¼ì˜ë¥¼ í†µí•´ì„œ ë§ì´ì£ . ê·¸ê²Œ ë°”ë¡œ ìš°ë¦¬ì˜ ì ‘ê·¼ë°©ì‹ì…ë‹ˆë‹¤.<br><br>ë§ˆì§„ ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ë©´, UAEì™€ ì¤‘ë™ ê°™ì€ ì¼ë¶€ ì§€ì—­ì€ ë¡œì—´í‹°ê°€ ì—†ìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ê·¸ê³³ì—ì„œ Dysportì— ëŒ€í•œ ê¶Œë¦¬ë¥¼ ë³´ìœ í•˜ì§€ ì•Šì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ì§€ì—­ë“¤ì€ ì •ë§ ë§¤ë ¥ì ì…ë‹ˆë‹¤. ì²˜ìŒë¶€í„° ë°”ë¡œ ê¸°ì—¬ë„ê°€ ë°œìƒí•˜ëŠ” ê±°ì£ . ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ Dysport ê¶Œë¦¬ë¥¼ ë³´ìœ í•œ ë‹¤ë¥¸ ì§€ì—­ë“¤ë„ ì—¬ëŸ¬ ê³³ì— ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê±°ê¸°ì„œëŠ” íŠ¹ì • ìˆ˜ì¤€ì„ ë‹¬ì„±í•´ì•¼ í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ë¯¸êµ­ì—ì„œëŠ” ìŠ¹ì¸ì´ ë‚˜ë©´ ì‹œì¥ ì„±ì¥ ê·œëª¨ë¥¼ ê³ ë ¤í•  ë•Œ ë‹¤ë¥¸ ì§€ì—­ë³´ë‹¤ í›¨ì”¬ ë¹ ë¥´ê²Œ ê·¸ ê¸°ì¤€ì ì— ë„ë‹¬í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ë¥¸ ì§€ì—­ì—ì„œëŠ” ë¡œì—´í‹°ë¥¼ ì§€ë¶ˆí•´ì•¼ í•˜ê¸° ë•Œë¬¸ì— ì¡°ê¸ˆ ë” ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ ë§¤ìš° ì¢‹ì€ ê¶¤ë„ë¥¼ ê·¸ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. í™˜ìë“¤ê³¼ ì˜ë£Œ ì „ë¬¸ê°€ë“¤ì´ ë¹ ë¥¸ íš¨ê³¼ ë°œí˜„ê³¼ ê¸´ ì§€ì† ì‹œê°„ì„ ë³´ê³  ë³´ì—¬ì£¼ëŠ” ì—´ì •, ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì§‘ì¤‘í•´ì•¼ í•  ë¶€ë¶„ì…ë‹ˆë‹¤. ìˆ˜ìµì„±ì€ ìì—°ìŠ¤ëŸ½ê²Œ ë”°ë¼ì˜¬ ê²ƒì´ê³  ìš°ë¦¬ì—ê²Œ ë§¤ìš° ë§¤ë ¥ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì€ ê±°ì˜ ì €ì ˆë¡œ í•´ê²°ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Emil Ivanov: Head of Strategy, Investor Relations & ESG Thank you very much for the question. Thank you, Thomas and Flemming for the answers. I will now pass over to Flemming to give his final remarks so that we can close the webcast.</td><td>**Emil Ivanov:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. Thomasì™€ Flemming, ë‹µë³€ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ Flemmingì—ê²Œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ ë¶€íƒë“œë¦¬ê³  ì›¹ìºìŠ¤íŠ¸ë¥¼ ë§ˆì¹˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: First of all, thank you so much for your thoughtful questions and also for your patience. I think you'll recognize that we're good at commercial execution, maybe we need to be a little bit better at meeting execution, but we always strive to improve. The good news was, it happened on a day when we had strong results, so you couldn't accuse us of trying to hide something. So as we highlighted today, we continue to be on a very strong trajectory, a very focused execution, both on our existing portfolio and new innovation. I can hear through the questions, you're very excited about a lot of new innovation, but don't forget, the vast majority of the growth is coming from our existing portfolio. We delivered USD 3.7 billion for the first 9 months, record, growing 15% at constant currency, widespread growth across product categories and geographies. Of course, you all honed in on Nemluvio, very strong growth in the U.S., but we also with neuromodulators that also showed very strong growth. We also had some benefit from some phasing in full transparency. A lot of questions from you U.S. tariffs. I think Thomas gave you a crystal clear answer with what we see today is factored into the 2025 guidance, but it is a bit of a moving target. U.S., as you can see, is very important for us, neuromodulators, Cetaphil, now Nemluvio. And of course, we also will invest significantly in the U.S., USD 650 million, as you may have read, U.S. dollar up to 2030 because we clearly need to increase our manufacturing footprint there. And given the importance of a number of products, Alastin, Nemluvio and Cetaphil, that's a necessary investment. And I think, as you've seen, strong growth trajectory, Nemluvio strong performance. We've updated our full year guidance, I think, not by a small percent, but significantly, both on top and bottom line. And with that, again, thank you so much for your thoughtful questions today, and have a great rest of the day.</td><td>**CEO & Director:** ë¨¼ì € ê¹Šì´ ìˆëŠ” ì§ˆë¬¸ë“¤ê³¼ ê¸°ë‹¤ë ¤ ì£¼ì‹  ì ì— ëŒ€í•´ ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì €í¬ê°€ ì˜ì—… ì‹¤í–‰ë ¥ì€ ë›°ì–´ë‚˜ë‹¤ëŠ” ì ì„ ì¸ì •í•˜ì‹œë¦¬ë¼ ìƒê°í•˜ëŠ”ë°, íšŒì˜ ì§„í–‰ì€ ì¡°ê¸ˆ ë” ê°œì„ í•  í•„ìš”ê°€ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. í•­ìƒ ë” ë‚˜ì•„ì§€ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤í–‰íˆ ì˜¤ëŠ˜ì€ ì‹¤ì ì´ ì¢‹ì€ ë‚ ì— ì´ëŸ° ì¼ì´ ë°œìƒí•´ì„œ, ë­”ê°€ë¥¼ ìˆ¨ê¸°ë ¤ í•œë‹¤ëŠ” ì˜¤í•´ëŠ” ë°›ì§€ ì•Šì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ê°•ì¡°ë“œë¦° ê²ƒì²˜ëŸ¼, ì €í¬ëŠ” ê¸°ì¡´ í¬íŠ¸í´ë¦¬ì˜¤ì™€ ì‹ ê·œ í˜ì‹  ì œí’ˆ ëª¨ë‘ì—ì„œ ë§¤ìš° ì§‘ì¤‘ëœ ì‹¤í–‰ì„ í†µí•´ ê°•ë ¥í•œ ì„±ì¥ ê¶¤ë„ë¥¼ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸ë“¤ì„ ë“¤ì–´ë³´ë‹ˆ ì—¬ëŸ¬ë¶„ê»˜ì„œ ë§ì€ ì‹ ì œí’ˆ í˜ì‹ ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ê³„ì‹  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, í•œ ê°€ì§€ ìŠì§€ ë§ì•„ì•¼ í•  ì ì€ ì„±ì¥ì˜ ëŒ€ë¶€ë¶„ì´ ê¸°ì¡´ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ë‚˜ì˜¤ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì²« 9ê°œì›” ë™ì•ˆ 37ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ê¸°ë¡ì ì¸ ìˆ˜ì¹˜ë¡œ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ 15% ì„±ì¥ì…ë‹ˆë‹¤. ì œí’ˆ ì¹´í…Œê³ ë¦¬ì™€ ì§€ì—­ ì „ë°˜ì— ê±¸ì³ ê´‘ë²”ìœ„í•œ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì—¬ëŸ¬ë¶„ ëª¨ë‘ Nemluvioì— ì£¼ëª©í•˜ì…¨ëŠ”ë°, ë¯¸êµ­ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„ ë³´ì˜€ê³ , ì‹ ê²½ì¡°ì ˆì œ(neuromodulators)ë„ ì—­ì‹œ ë§¤ìš° ê°•í•œ ì„±ì¥ì„¸ë¥¼ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. ì™„ì „íˆ íˆ¬ëª…í•˜ê²Œ ë§ì”€ë“œë¦¬ë©´, ì¼ë¶€ ë‹¨ê³„ì  íš¨ê³¼(phasing)ë¡œ ì¸í•œ ì´ìµë„ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>ì—¬ëŸ¬ë¶„ê»˜ì„œ ë¯¸êµ­ ê´€ì„¸ì— ëŒ€í•´ ë§ì€ ì§ˆë¬¸ì„ ì£¼ì…¨ìŠµë‹ˆë‹¤. Thomasê°€ ëª…í™•í•˜ê²Œ ë‹µë³€ë“œë ¸ë‹¤ê³  ìƒê°í•˜ëŠ”ë°, í˜„ì¬ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ìƒí™©ì€ 2025ë…„ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë‹¤ì†Œ ìœ ë™ì ì¸ ëª©í‘œì´ê¸´ í•©ë‹ˆë‹¤. <br><br>ë³´ì‹œë‹¤ì‹œí”¼ ë¯¸êµ­ì€ ìš°ë¦¬ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ì‹œì¥ì…ë‹ˆë‹¤. ì‹ ê²½ì¡°ì ˆì œ, Cetaphil, ê·¸ë¦¬ê³  ì´ì œ Nemluvioê¹Œì§€ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ë¯¸êµ­ì— ìƒë‹¹í•œ íˆ¬ìë„ í•  ê²ƒì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ì´ ì½ìœ¼ì…¨ì„ ìˆ˜ë„ ìˆëŠ”ë°, 6ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ê·œëª¨ì…ë‹ˆë‹¤. 2030ë…„ê¹Œì§€ 10ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•  ê³„íšì…ë‹ˆë‹¤. í˜„ì§€ ìƒì‚° ê¸°ë°˜ì„ í™•ëŒ€í•´ì•¼ í•˜ëŠ” ê²ƒì´ ëª…í™•í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì•Œë¼ìŠ¤í‹´(Alastin), ë„´ë£¨ë¹„ì˜¤(Nemluvio), ì„¸íƒ€í•„(Cetaphil) ë“± í•µì‹¬ ì œí’ˆë“¤ì˜ ì¤‘ìš”ì„±ì„ ê³ ë ¤í•  ë•Œ ë°˜ë“œì‹œ í•„ìš”í•œ íˆ¬ìì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ê°•ë ¥í•œ ì„±ì¥ ê¶¤ë„ë¥¼ ë³´ì´ê³  ìˆê³ , ë„´ë£¨ë¹„ì˜¤ë„ íƒì›”í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì—°ê°„ ê°€ì´ë˜ìŠ¤ë„ ìƒí–¥ ì¡°ì •í–ˆëŠ”ë°, ì†Œí­ì´ ì•„ë‹ˆë¼ ë§¤ì¶œê³¼ ìˆ˜ìµ ì–‘ìª½ ëª¨ë‘ì—ì„œ ìƒë‹¹í•œ ìˆ˜ì¤€ìœ¼ë¡œ ì˜¬ë ¸ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì¢‹ì€ ì§ˆë¬¸ë“¤ ì£¼ì…”ì„œ ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ë“œë¦¬ê³ , ë‚¨ì€ í•˜ë£¨ ì¢‹ì€ ì‹œê°„ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes today's conference call. Thank you for participating. You may all disconnect. Have a nice day.</td><td>**Operator:** ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ì¢‹ìŠµë‹ˆë‹¤. ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì„¸ìš”.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Galderma Q3 2025 ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì„±ê³¼<br>- **9ê°œì›” ëˆ„ì  ë§¤ì¶œ USD 3.737ì–µ ë‹¬ëŸ¬ ë‹¬ì„±**, ê³ ì •í™˜ìœ¨ ê¸°ì¤€ 15% ì„±ì¥<br>- ë¯¸êµ­ ì‹œì¥ 17.5%, êµ­ì œ ì‹œì¥ 12% ì´ìƒ ì„±ì¥í•˜ë©° ì „ ì§€ì—­ì—ì„œ ê³ ë¥¸ ì„±ì¥ì„¸<br>- ì£¼ì‚¬í˜• ë¯¸ìš© ì œí’ˆ, ì¹˜ë£Œìš© í”¼ë¶€ê³¼ ì œí’ˆ ëª¨ë‘ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ ê¸°ë¡<br>- **2025ë…„ ì—°ê°„ ê°€ì´ë˜ìŠ¤ ìƒí–¥ ì¡°ì •** (ë§¤ì¶œ ë° ì´ìµ ëª¨ë‘)<br><br>## Nemluvio ì„±ê³¼ ë° ì „ë§<br>- 9ê°œì›” ëˆ„ì  ë§¤ì¶œ USD 263ë°±ë§Œ ë‹¬ëŸ¬ ë‹¬ì„±, ì‹œì¥ ì˜ˆìƒ ìƒíšŒ<br>- AD(ì•„í† í”¼ í”¼ë¶€ì—¼) ì‹œì¥ NBRx ì ìœ ìœ¨ 7.2%, PN(ê²°ì ˆì„± ì–‘ì§„) 37% ë‹¬ì„±<br>- **ìƒì—… ë³´í—˜ ì»¤ë²„ë¦¬ì§€ 80% ì´ìƒ í™•ë³´**, 2026ë…„ Medicare/Medicaid ì§„ì… ì˜ˆì •<br>- 3ë¶„ê¸°ì— AD ì ì‘ì¦ì´ PNì„ ì´ˆê³¼í•˜ë©° ê°€ì¥ í° ë§¤ì¶œ ê¸°ì—¬<br>- í™˜ì ì´íƒˆë¥  ë§¤ìš° ë‚®ê³ , 4ì£¼ íˆ¬ì—¬ì—ì„œ 8ì£¼ íˆ¬ì—¬ë¡œ ì „í™˜ ì‹œì‘<br>- ì†ìµë¶„ê¸°ì  2027ë…„ ì˜ˆìƒ ìœ ì§€, í”¼í¬ ë§¤ì¶œ $2B+ ê°€ì´ë˜ìŠ¤ í–¥í›„ ì¬ê²€í†  ê°€ëŠ¥<br><br>## ê²½ì˜ì§„ í†¤ ë° ì „ëµì  í¬ì¸íŠ¸<br>- **í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ ê· í˜•ì¡íŒ ì„±ì¥ ê°•ì¡°** - Nemluvioë§Œì´ ì•„ë‹Œ</p>
    <hr style="margin:50px 0;">
    
</body></html>